WO1989012641A1 - Enterically transmitted non-a/non-b hepatitis viral agent - Google Patents
Enterically transmitted non-a/non-b hepatitis viral agent Download PDFInfo
- Publication number
- WO1989012641A1 WO1989012641A1 PCT/US1989/002435 US8902435W WO8912641A1 WO 1989012641 A1 WO1989012641 A1 WO 1989012641A1 US 8902435 W US8902435 W US 8902435W WO 8912641 A1 WO8912641 A1 WO 8912641A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- derived
- nanb
- viral
- homologous
- Prior art date
Links
- 206010019799 Hepatitis viral Diseases 0.000 title claims abstract description 25
- 201000001862 viral hepatitis Diseases 0.000 title claims abstract description 25
- 239000012634 fragment Substances 0.000 claims abstract description 130
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 53
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 51
- 239000000523 sample Substances 0.000 claims abstract description 47
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 230000003612 virological effect Effects 0.000 claims abstract description 44
- 208000015181 infectious disease Diseases 0.000 claims abstract description 29
- 230000003321 amplification Effects 0.000 claims abstract description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 64
- 102000036639 antigens Human genes 0.000 claims description 46
- 108091007433 antigens Proteins 0.000 claims description 46
- 239000000427 antigen Substances 0.000 claims description 44
- 108020004414 DNA Proteins 0.000 claims description 42
- 239000013612 plasmid Substances 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 25
- 241000588724 Escherichia coli Species 0.000 claims description 24
- 210000000941 bile Anatomy 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 21
- 101100438142 Drosophila melanogaster cac gene Proteins 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 15
- 208000006454 hepatitis Diseases 0.000 claims description 14
- 231100000283 hepatitis Toxicity 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 241000282567 Macaca fascicularis Species 0.000 claims description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 11
- 108091026890 Coding region Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 48
- 108010067390 Viral Proteins Proteins 0.000 abstract description 12
- 238000012163 sequencing technique Methods 0.000 abstract description 7
- 238000002405 diagnostic procedure Methods 0.000 abstract description 6
- 239000003298 DNA probe Substances 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 description 41
- 239000002245 particle Substances 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 34
- 230000027455 binding Effects 0.000 description 20
- 238000003556 assay Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 239000013615 primer Substances 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 14
- 108020004635 Complementary DNA Proteins 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 108010005774 beta-Galactosidase Proteins 0.000 description 11
- 239000012491 analyte Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 230000003302 anti-idiotype Effects 0.000 description 9
- 102000005936 beta-Galactosidase Human genes 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 239000013599 cloning vector Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000001042 affinity chromatography Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001502 gel electrophoresis Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 108020005038 Terminator Codon Proteins 0.000 description 4
- 230000002155 anti-virotic effect Effects 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000001493 electron microscopy Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000164 protein isolation Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000028744 lysogeny Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000002064 post-exposure prophylaxis Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001244729 Apalis Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- This invention relates to recombinant proteins, genes, and gene probes and more specifically to such proteins and probes derived from an enterically transmitted nonA/nonB hepatitis viral agent, and to diagnostic methods and vaccine applications which employ the proteins and probes.
- Enterically transmitted non-A/non-B (ET-NANB) hepatitis viral agent is the reported cause of hepatitis in several epidemics and sporadic cases in Asia, Africa, and the Indian subcontinent. Infection is usually by water contaminated with feces, although the virus may also spread by close physical contact. The virus does not seem to cause chronic infection.
- the viral etiology in ET-NANB has been demonstrated by infection of volunteers with pooled fecal isolates; Immune electron microscopy (IEM) studies have shown virus particles with 27-34 nm diameters in stools from infected individuals. The virus particles reacted with antibodies in serum from infected individuals from geographically distinct regions, suggesting that a single viral agent or class is responsible for the majority of ET-NANB hepatitis seen worldwide. No antibody reaction was seen in serum from individuals infected with blood-transmitted NANB virus, indicating a different specificity between the two NANB types. In addition to serological differences, the two types of NANB infection show distinct clinical differences.
- ET-NANB is characteristically an acute infection, often associated with fever and arthralgia, and with portal inflammation and associated bile stasis in liver biopsy specimens (Arankalle). Symptoms are usually resolved within six weeks. Blood-transmitted NANB, by contrast, produces a chronic infection in about 50% of the cases. Fever and arthralgia are rarely seen, and inflammation has a predominantly parenchymal distribution (Khuroo, 1980). The two viral agents can also be distinguished on the basis of primate host susceptibility. ET-NANB, but not the blood-transmitted agent, can be transmitted to cynomolgus monkeys. The blood-transmitted agent is more readily transmitted to chimpanzees than is ET-NANB (Bradley, 1987).
- compositions as well as methods of preparation and use of the compositions are provided, where the compositions comprise viral proteins and fragments thereof derived from the viral agent for ET- NANB.
- Methods for preparation of ET-NANB viral proteins include isolating ET-NANB genomic sequences which are then cloned and expressed in a host cell. The resultant recombinant viral proteins find use as diagnostic agents and as vaccines. The genomic sequences and fragments thereof find use in preparing ET-NANB viral proteins and as probes for virus detection.
- Figure 1 shows vector constructions and manipulations used in obtaining and sequencing cloned ET-NANB fragment
- Figures 2A-2B are representations of Southern blots in which a radiolabeled ET-NANB probe was hybridized with amplified cDNA fragments prepared from RNA isolated from infected (I) and non-infected (N) bile sources (2A), and from infected (I) and non- infected (N) stool-sample sources (2B).
- compositions comprising generic sequences and fragments thereof derived from the viral agent for ET-NANB are provided, together with recombinant viral proteins produced using the genomic sequences and methods of using these compositions.
- the genome of the ET-NANB viral agent is identified as containing a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ- KF1 (ET1.1) carried in E. coli strain BB4 and having ATCC deposit no. 67717.
- Initial studies sequenced the two terminal regions of the insert and an intermediate region. The 5'-end region of this insert contains the sequence:
- An intermediate region has the sequence:
- CAG GCC CCG AAG GAG TCT CTG CGA GGG TTT TGG AAG AAA CAC
- the 3'-end region contains the sequence:
- the complimentary strand referred to here as the "reverse sequence,” is set forth below in the same manner as the forward sequence set forth above.
- hepatitis viral agent means a virus, virus type, or virus class which (1) causes water-borne, infectious hepatitis, (ii) is transmissible in cynomolgus monkeys, (iii) is serologically distinct from hepatitis A virus ( ⁇ AV) and hepatitis B virus (HAB), and (iv) includes a genomic region which is homologous to the 1.33 kb cDNA insert in plasmid pTZ-KFl(ETl.l) carried in E. coli strain BB4 identified by ATCC deposit number 67717.
- Two double-strand nucleic acid fragments are "homologous" if their opposite strands are capable of hybridizing to one another under moderately stringent hybridization conditions, i.e., where hybridized strands contain at most about 5-10% basepair mismatches.
- a single-strand nucleic acid species is homologous to a double-strand fragment if it contains a region which is capable of hybridizing to one of the fragment strands under moderately stringent hybridization conditions.
- a DNA fragment is "derived from" an ET-NANB viral agent if it has the same or substantially the same basepair sequence as a region of the viral agent genome.
- a protein is "derived from" an ET-NANB viral agent if it is encoded by an open reading frame of a DNA or RNA fragment derived from an ET-NANB viral agent.
- a virus-specific DNA clone can be produced by (a) isolating RNA from the bile of a cynomolgus monkey having a known ET-NANB infection, (b) cloning the cDNA fragments to form a fragment library, and (c) screening the library by differential hybridization to radiolabeled cDNAs from infected and non-infected bile sources.
- ET-NANB infection in cynomolgus monkeys is initiated by inoculating the animals intravenously with a 10% w/v suspension from human case stools positive for 27-34 nm ET-NANB particles (mean diameter 32 nm) .
- An infected animal is monitored for elevated levels of alanine aminotransferase, indicating hepatitis infection.
- ET-NANB infection is confirmed by immunospecific binding of seropositive antibodies to virus-like particles (VLPs), according to published methods (Gravelle).
- a stool (or bile) specimen taken from the infected animal 3-4 weeks after infection is diluted 1:10 with phosphate-buffered saline, and the 10% suspension is clarified by low- speed centrifugation and filtration successively through 1.2 and 0.45 micron filters.
- the material may be further purified by pelleting through a 30% sucrose cushion (Bradley).
- the resulting preparation of VLPs is mixed with diluted serum from human patients with known ET-NANB infection. After incubation overnight, the mixture is centrifuged overnight to pellet immune aggregates, and these are stained and examined by electron microscopy for antibody binding to the VLPs. ET-NANB infection can also be confirmed by seroconversion to VLP-positive serum.
- RNA is extracted from the bile by hot phenol extraction, as outlined in Example IA.
- the RNA fragments are used to synthesize corresponding duplex cDNA fragments by random priming, also as referenced in Example IA.
- the cDNA fragments may be fractionated by gel electrophoresis or density gradient centrifugation to obtain a desired size class of fragments, e.g., 500-4,000 basepair fragments.
- bile source is preferred.
- bile from ET-NANB-infected monkeys shows a greater number of intact viral particles than material obtained from stool samples, as evidenced by immune electron microscopy.
- cDNA Library and Screening The cDNA fragments from above are cloned into a suitable cloning vector to form a cDNA library. This may be done by equipping blunt-ended fragments with a suitable end linker, such as an EcoRI sequence, and inserting the fragments into a suitable insertion site of a cloning vector, such as at a unique EcoRI site. After initial cloning, the library may be recloned, if desired, to increase the percentage of vectors containing a fragment insert.
- the library construction described in Example IB is illustrative. Here cDNA fragments were blunt-ended, equipped with EcoRI ends, and inserted into the EcoRI site of the lambda phage vector gtlO. The library phage, which showed less than 5% fragment inserts, was isolated, and the fragment inserts recloned into the lambda gtlO vector, yielding more than 95% insert-containing phage.
- the cDNA library is screened for sequences specific for ET-NANB by differential hybridization to cDNA probes derived from infected and non-infected sources.
- cDNA fragments from infected and non-infected source bile or stool viral isolates can be prepared as above. Radiolabeling the fragments is by random labeling, nick translation, or end labeling, according to conventional methods (Maniatis, p. 109).
- the cDNA library from above is screened by transfer to duplicate nitrocellulose filters, and hybridization with both infected-source and non-infected-source (control) radiolabeled probes, as detailed in Example 2.
- Plaques which show selective hybridization to the infected- source probes are preferably replated at low plating density and rescreened as above, to isolate single clones which are specific for ET-NANB sequences. As indicated in Example 2, sixteen clones which hybridized specifically with infected-source probes were indentified by these procedures.
- the basepair sequence of cloned regions of the ET-NANB fragments from Part B are determined by standard sequencing methods.
- the fragment insert from the selected cloning vector is excised, isolated by gel electrophoresis, and inserted into a cloning vector whose basepair sequence on either side of the insertion site is known.
- the particular vector employed in Example 3 is a pTZ-KFl vector shown at the left in Figure 1.
- the ET-NANB fragment from the gtlO- 1.1 phage was inserted at the unique EcoRI site of the pTZ-KFl plasmid. Recombinants carrying the desired insert were identified by hybridization with the isolated 1.33 kilobase fragment, as described in Example 3.
- E. coli strain BB4 infected with the pTZ-KFl(ETl.l) plasmid has been deposited with the American Type Culture Collection, Rockville, MD, and is identified by ATCC deposit nubmer 67717.
- the pTZ-KFl(ETl.l) plasmid is illustrated at the bottom in Figure 1.
- the fragment insert has 5' and 3' end regions denoted at A and C, respectively, and an intermediate region, denoted at B.
- the sequences in these regions were determined by standard dideoxy sequencing and are set forth above.
- the three short sequences (A, B, and C) are from the same insert strand.
- the B-region sequence was actually determined from the opposite strand, so that the B-region sequence shown above represent the complement of the sequence in the sequenced strand.
- the base numbers of the partial sequences are approximate.
- Pattern identifier Pattern matched Base number matched ( ⁇ cleavage site) in "forward" strand
- GWGCVTC GgiAI
- the invention includes ET-NANB-specific fragments or probes which hybridize with ET-NANB genomic sequences or cDNA fragments derived therefrom.
- the fragments may include full-length cDNA fragments such as described in Section II, or may be derived from shorter sequence regions within cloned cDNA fragments. Shorter fragments can be prepared by enzymatic digestion of full-length fragments under conditions which yield desired-sized fragments, as will be described in Section IV. Alternatively, the fragments can be produced by oligonucleotide synthetic methods, using sequences derived from the cDNA fragments. Methods or services for producing selected-sequence oligonucleotide fragments are available.
- the fragment can be shown to hybridize selectively with cDNA from infected sources.
- the fragment was excised from the pTZ-KFl(ETl.l) plasmid, purified, and radiolabeled by random labeling. The radiolabeled fragment was hybridized with fractionated cDNAs from infected and non-infected sources to confirm that the probe reacts only with infected-source cDNAs.
- Example 4 This method is illustrated in Example 4, where the above radiolabeled 1.33 kb fragment from pTZ-KFl(ETl.l) plasmid was examined for binding to cDNAs prepared from infected and non-infected sources.
- the infected sources are (1) bile from a cynomolgus monkey infected with a strain of virus derived from stool samples from human patients from Burma with known ET-NANB infections and (2) a viral agent derived from the stool sample of a human ET-NANB patient from Mexico.
- the cDNAs in each fragment mixture were first amplified by a linker/primer amplification method described in Example 4.
- Fragment separation was on agarose gel, followed by Southern blotting and then hybridization to bind the radiolabeled 1.33 kb fragment to the fractionated cDNAs.
- the lane containing cDNAs from the infected sources showed a smeared band of bound probe, as expected (cDNAs amplified by the linker/primer amplification method would be expected to have a broad range of sizes). No probe binding to the amplified cDNAs from the non-infected sources was observed. The results indicate that the 1.33 kb probe is specific for cDNA fragments associated with ET-NANB infection.
- Procedures for identifying additional ET-NANB library clones and generating new probes therefrom generally follow the cloning and selection procedures described in Section II.
- the fragments (and oligonucleotides prepared based on the sequences given above) are also useful as primers for a poly erase chain reaction method of detecting ET-NANB viral genomic material in a patient sample. This diagnostic method will be described in Section V below.
- ET-NANB proteins can be prepared by expressing open reading-frame coding regions in ET-NANB fragments.
- the ET-NANB fragments used for protein expression are derived from cloned cDNAs which have been treated to produce desired-size fragments, and preferably random fragments with sizes predominantly between about 100 to about 300 base pairs.
- Example 5 describes the preparation of such fragments by DNAs digestion. Because it is desired to obtain peptide antigens of between about 30 to about 100 amino acids, the digest fragments are preferably size fractionated, for example by gel electrophoresis, to select those in the approximately 100-300 basepair size range.
- the ET-NANB fragments are inserted into a suitable expression vector.
- One exemplary expression vector is lambda gtll, which contains a unique EcoRI insertion site 53 base pairs upstream of the translation termination codon of the beta-galactosidase gene.
- the inserted sequence will be expressed as a beta-galactosidase fusion protein which contains the N-terminal portion of the beta-galactosidase gene, the heterologous peptide, and optionally the C-terminal region of the beta-galactosidase peptide (the C- terminal portion being expressed when the heterologous peptide coding sequence does not contain a translation termination codon).
- This vector also produces a temperature-sensitive repressor (cl857) which causes viral lysogeny at permissive temperatures, e.g., 32°C, and leads to viral lysis at elevated temperatures, e.g., 42°C.
- Advantages of this vector include: (1) highly efficient recombinant generation, (2) ability to select lysogenized host cells on the basis of host-cell growth at permissive, but not non-permissive, temperatures, and (3) high levels of recombinant fusion protein production.
- phage containing a heterologous insert produces an inactive beta- galactosidase enzyme, phage with inserts can be readily identified by a beta-galactosidase colored-substrate reaction.
- the viral digest fragments may be modified, if needed, to contain selected restriction-site linkers, such as EcoRI linkers, according to conventional procedures.
- Example 1 illustrates methods for cloning the digest fragments into lambda gtll, which includes the steps of blunt-ending the fragments, ligating with EcoRI linkers, and introducing the fragments into EcoRI-cut lambda gtll.
- the resulting viral genomic library may be checked to confirm that a relatively large (representative) library has been produced. This can be done, in the case of the lambda gtll vector, by infecting a suitable bacterial host, plating the bacteria, and examining the plaques for loss of beta- galactosidase activity. Using the procedures described in Example 1, about 50% of the plaques showed loss of enzyme activity.
- the viral genomic library formed above is screened for production of peptide antigen (expressed as a fusion protein) which is immunoreactive with antiserum from ET-NANB seropositive individuals.
- host cells infected with phage library vectors are plated, as above, and the plate is blotted with a nitrocellulose filter to transfer recombinant protein antigens produced by the cells onto the filter.
- the filter is then reacted with the ET-NANB antiserum, washed to remove unbound antibody, and reacted with reporter-labeled, anti-human antibody, which becomes bound to the filter, in sandwich fashion, through the anti-ET-NANB antibody.
- phage plaques which are identified by virtue of their production of recombinant antigen of interest are re-examined at a relatively low density for production of antibody-reactive fusion protein.
- Several recombinant phage clones which produced immunoreactive recombinant antigen were identified in the procedure.
- the selected expression vectors may be used for scale-up production, for purposes of recombinant protein purification.
- Scale-up production is carried out using one of a variety of reported methods for (a) lysogenizing a suitable host, such as E. coli, with a selected lambda gtll recombinant (b) culturing the transduced cells under conditions that yield high levels of the heterologous peptide, and (c) purifying the recombinant antigen from the lysed cells.
- a high-producer E. coli host, BNN103 is infected with the selected library phage and replica plated on two plates.
- One of the plates is grown at 32 ⁇ C, at which viral lysogeny can occur, and the other at 42°C, at which the infecting phage is in a lytic stage and therefore prevents cell growth. Cells which grow at the lower but not the higher temperature are therefore assumed to be successfully lysogenized.
- the lysogenized host cells are then grown under liquid culture conditions which favor high production of the fused protein containing the viral insert, and lysed by rapid freezing to release the desired fusion protein.
- the recombinant peptide can be purified by standard protein purification procedures which may include differential precipitation, molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis and affinity chromatography.
- a fused protein such as the beta-galactosidase fused protein prepared as above
- the protein isolation techniques which are used can be adapted from those used in isolation of the native protein.
- the protein can be isolated readily by simple affinity chromatography, by passing the cell lysis material over a solid support having surface-bound anti-beta-galactosidase antibody.
- the ET-NANB protein of the invention may also be derived directly from the ET-NANB viral agent.
- VLPs isolated from a stool sample from an infected individual, as above, are one suitable source of viral protein material.
- the VLPs isolated from the stool sample may be further purified by affinity chromatography prior to protein isolation (see below).
- the viral agent may also be raised in cell culture, which provides a convenient and potentially concentrated source of viral protein.
- Co-owned U.S. Patent Application Serial No. 846,757, filed April 1, 1986 describes an immortalized trioma liver cell which supports NANB infection in cell culture.
- the trioma cell line is prepared by fusing human liver cells with a mouse/human fusion partner selected for human chromosome stability.
- Cells containing the desired NANB viral agent can be identified by immuno- fluorescence methods, employing anti-ET-NANB human antibodies.
- the viral agent is disrupted, prior to protein isolation, by conventional methods, which can include sonication, high- or low-salt conditions, or use of detergents.
- ET-NANB viral protein can be carried out by affinity chromatography, using a purified anti-ET-NANB antibody attached according to standard methods to a suitable solid support.
- the antibody itself may be purified by affinity chromatography, where an immunoreactive recombinant ET- NANB protein, such as described above, is attached to a solid support, for isolation of anti-ET-NANB antibodies from an immune serum source. The bound antibody is released from the support by standard methods.
- the anti-ET-NANB antibody may be a monoclonal antibody (Mab) prepared by immunizing a mouse or other animal with recombinant ET-NANB protein, isolating lymphocytes from the animal and immortalizing the cells with a suitable fusion partner, and selecting successful fusion products which react with the recombinant protein immunogen. These in turn may be used in affinity purification procedures, described above, to obtain native ET-NANB antigen.
- Mob monoclonal antibody
- the particles and antigens of the invention, as well as the genetic material, can be used in diagnostic assays.
- Methods for detecting the presence of ET-NANB hepatitis comprise analyzing a biological sample such as a blood sample, stool sample or liver biopsy specimen for the presence of an analyte associated with ET-NANB hepatitis virus.
- the analyte can be a nucleotide sequence which hybridizes with a probe comprising a sequence of at least about 16 consecutive nucleotides, usually 30 to 200 nucleotides, up to substantially the full sequence of the sequences shown above (cDNA sequences).
- the analyte can be RNA or cDNA.
- the analyte is typically a virus particle suspected of being ET-NANB or a particle for which this classification is being ruled out.
- the virus particle can be further characterized as having an RNA viral genome comprising a sequence at least about 80% homologous to a sequence of at least 12 consecutive nucleotides of the "forward" and "reverse” sequences given above, usually at least about 90% homologous to at least about 60 consecutive nucleotides within the sequences, and may comprise a sequence substantially homologous to the full-length sequences.
- the probe may contain a detectable label.
- the analyte can also comprise an antibody which recognizes an antigen, such as a cell surface antigen, on a ET-NANB virus particle.
- the analyte can also be a ET-NANB viral antigen.
- the analyte is an antibody or an antigen
- either a labelled antigen or antibody, respectively can be used to bind to the analyte to form an immunological complex, which can then be detected by means of the label.
- methods for detecting analytes such as surface antigens and/or whole particles are based on i munoassays.
- I munoassays can be conducted either to determine the presence " of antibodies in the host that have arisen from infection by ET-NANB hepatitis virus or by assays that directly determine the presence of virus particles or antigens. Such techniques are well known and need not be described here in detail. Exam ⁇ ples include both heterogeneous and homogeneous immuno- assay techniques. Both techniques are based on the formation of an immunological complex between the virus particle or its antigen and a corresponding specific antibody. Heterogeneous assays for viral antigens typically use a specific monoclonal or polyclonal antibody bound to a solid surface. Sandwich assays are becoming increasingly popular.
- Homogeneous assays which are carried out in solution without the presence of a solid phase, can also be used, for example by determining the difference in enzyme activity brought on by binding of free antibody to an enzyme-antigen conjugate.
- a number of suitable assays are disclosed in U.S. Patent Nos. 3,817,837, 4,006,360, 3,996,345.
- the viruses and antigens of the invention can be used as specific binding agents to detect either IgG or IgM antibodies.
- IgM anti ⁇ bodies are typically the first antibodies that appear during the course of an infection, when IgG synthesis may not yet have been initiated, specifically distin ⁇ guishing between IgM and IgG antibodies present in the blood stream of a host will enable a physician or other investigator to determine whether the infection is recent or chronic.
- test serum is reacted with a solid phase reagent having surface-bound ET-NANB protein antigen.
- the reagent After binding anti-ET-NANB antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-ET-NANB antibody on the solid support.
- the reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined.
- the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric or colorimetric substrate.
- the solid surface reagent in the above assay prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activate carboxyl, hydroxyl, or aldehyde group.
- homogeneous assay In a second diagnostic configuration, known as a homogeneous assay, antibody binding to a solid support produces some change in the reaction medium which can be directly detected in the medium.
- Known general types of homogeneous assays proposed heretofore include (a) spin-labeled reporters, where antibody binding to the antigen is detected by a change in reported mobility (broadening of the spin splitting peaks), (b) fluorescent reporters, where binding is detected by a change in fluorescence efficiency, (c) enzyme reporters, where antibody binding effects enzyme/substrate interactions, and (d) liposome-bound reporters, where binding leads to liposome lysis and release of encapsulated reporter.
- spin-labeled reporters where antibody binding to the antigen is detected by a change in reported mobility (broadening of the spin splitting peaks)
- fluorescent reporters where binding is detected by a change in fluorescence efficiency
- enzyme reporters where antibody binding effects enzyme/substrate interactions
- liposome-bound reporters where binding leads to lipo
- the assay method involves reacting the serum from a test individual with the protein antigen and examining the antigen for the presence of bound antibody.
- the examining may involve attaching a labeled anti-human antibody to the antibody being examined, either IgM (acute phase) or IgG (convalescent phase), and measuring the amount of reporter bound to the solid support, as in the first method, or may involve observing the effect of antibody binding on a homogeneous assay reagent, as in the second method.
- kits for carrying out the assay method just described.
- the kit generally includes a support with surface-bound recombinant protein antigen which is (a) immunoreactive with antibodies present in individuals infected with enterically transmitted nonA/nonB viral agent and (b) derived from a viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ- KFl(ETl.l) carried in E. Coli strain BB4, and having ATCC deposit no. 67717.
- a reporter-labeled anti-human antibody in the kit is used for detecting surface-bound anti-ET-NANB antibody.
- the genetic material of the invention can it ⁇ self be used in numerous assays as probes for genetic material present in naturally occurring infections.
- One method for amplification of target nucleic acids, for later analysis by hybridization assays, is known as the polymerase chain reaction or PCR technique.
- the PCR technique can be applied to detecting virus particles of the invention in suspected pathological samples using oligonucleotide primers spaced apart from each other and based on the genetic sequence set forth above.
- the primers are complementary to opposite strands of a double stranded DNA molecule and are typically separated by from about 50 to 450 nt or more (usually not more than 2000 nt).
- This method entails preparing the specific oligonucleotide primers and then repeated cycles of target DNA denaturation, primer binding, and extension with a DNA polymerase to obtain DNA fragments of the expected length based on the primer spacing. Extension products generated from one primer serve as additional target sequences for the other primer.
- the degree of amplification of a target sequence is controlled by the number of cycles that are performed and is theoretically calculated by the simple formula 2 n where n is the number of cycles. Given that the average efficiency per cycle ranges from about 65% to 85%, 25 cycles produce from 0.3 to 4.8 million copies of the target sequence.
- the PCR method is de ⁇ scribed in a number of publications, including Saiki e_t ⁇ !•» Science (1985) 23_0:1350-1354; Saiki et al. , Nature (1986) 3_24_:163-166; and Scharf et al. , Science (1986) 2_3_3:1076-1078. Also see U.S. Patent Nos. 4,683,194; 4,683,195; and 4,683,202.
- the invention includes a specific diagnostic method for determination of ET-NANB viral agent, based on selective amplification of ET-NANB fragments.
- This method employs a pair of single-strand primers derived from non-homologous regions of opposite strands of a DNA duplex fragment, which in turn is derived from an enterically transmitted viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ- KFl(ETl.l) carried in E. coli strain BB4, and having ATCC deposit no. 67717.
- These "primer fragments,” which form one aspect of the invention, are prepared f om ET-NANB fragments such as described in Section III above.
- the method follows the process for amplifying selected nucleic acid sequences as disclosed in U.S. Patent No. 4,683,202, as discussed above.
- any of the antigens of the invention can be used in preparation of a vaccine.
- a preferred starting material for preparation of a vaccine is the particle antigen isolated from bile.
- the antigens are preferably initially recovered as intact particles as described above. However, it is also possible to pre- pare a suitable vaccine from particles isolated from other sources or non-particle recombinant antigens.
- non-particle antigens typically soluble antigens
- proteins derived from the viral envelope or viral capsid are preferred for use in preparing vac- cines. These proteins can be purified by affinity chromatography, also described above.
- the purified protein is not immunogenic per se, it can be bound to a carrier to make the protein immunogenic.
- Carriers include bovine serum albumin, keyhole limpet hemocyanin and the like. It is desir ⁇ able, but not necessary, to purify antigens to be sub ⁇ stantially free of human protein. However, it is more important that the antigens be free of proteins, viruses, and other substances not of human origin that may have been introduced by way of, or contamination of, the nutrient medium, cell lines, tissues, or patho- logical fluids from which the virus is cultured or obtained.
- Vaccination can be conducted in conventional fashion.
- the antigen whether a viral particle or a protein
- a suitable diluent such as water, saline, buffered salines, complete or incomplete adjuvants, and the like.
- the immunogen is administered using standard techniques for antibody induction, such as by subcutaneous administra ⁇ tion of physiologically compatible, sterile solutions containing inactivated or attenuated virus particles or antigens.
- An immune response producing amount of virus particles is typically administered per vaccinizing injection, typically in a volume of one milliliter or less.
- a specific example of a vaccine composition includes, in a pharmacologically acceptable adjuvant, a recombinant protein or protein mixture derived from- an enterically transmitted nonA/nonB viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ- KFl(ETl.l) carried in E. coli strain BB4, and having ATCC deposit no. 67717.
- the vaccine is administered at periodic intervals until a significant titer of anti- ET-NANB antibody is detected in the serum.
- the vaccine is intended to protect against ET-NANB infection.
- the composi- tions can be used to prepare antibodies to ET-NANB virus particles.
- the antibodies can be used directly as antiviral agents.
- a host animal is immunized using the virus particles or, as appropriate, non-particle antigens native to the virus particle are bound to a carrier as described above for vaccines.
- the host serum or plasma is collected following an appropriate time interval to provide a composition comprising antibodies reactive with the virus particle.
- the gamma globulin fraction or the IgG antibodies can be obtained, for example, by use of saturated ammonium sulfate or DEAE Sephadex, or other techniques known to those skilled in the art.
- the antibodies are substantially free of many of the adverse side effects which may be associated with other anti-viral agents such as drugs.
- the antibody compositions can be made even more compatible with the host system by minimizing potential adverse immune system responses. This is accomplished by removing all or a portion of the Fc portion of a foreign species antibody or using an antibody of the same species as the host animal, for example, the use of antibodies from human/human hybridomas.
- the antibodies can also be used as a means of enhancing the immune response since antibody-virus complexes are recognized by macrophages.
- the anti ⁇ bodies can be administered in amounts similar to those used for other therapeutic administrations of anti ⁇ body.
- pooled gamma globulin is admini ⁇ stered at 0.02-0.1 ml/lb body weight during the early incubation of other viral diseases such as rabies, measles and hepatitis B to interfere with viral entry into cells.
- antibodies reactive with the ET-NANB virus particle can be passively administered alone or in conjunction with another anti-viral agent to a host infected with an ET-NANB virus to enhance the immune response and/or the effectiveness of an antiviral drug.
- anti-ET-NANB-virus antibodies can be induced by administering anti-idiotype anti ⁇ bodies as immunogens.
- a purified anti- ET-NANB-virus antibody preparation prepared as descibed above is used to induce anti-idiotype antibody in a host animal.
- the composition is administered to the host animal in a suitable diluent. Following administration, usually repeated administration, the host produces anti-idiotype antibody.
- antibodies pro ⁇ **d by the same species as the host animal can be used or the Fc region of the administered antibodies can be removed.
- serum or plasma is removed to provide an antibody composition.
- the composition can be purified as described above for anti-ET-NANB- virus antibodies, or by affinity chromatography using anti-ET-NANB-virus antibodies bound to the affinity matrix.
- the anti-idiotype antibodies produced are similar in conformation to the authentic ET-NANB antigen and may be used to prepare an ET-NANB vaccine rather than using a ET-NANB particle antigen.
- the manner of injecting the antibody is the same as for vaccination purposes, namely intramuscularly, intraperitoneally, subcutane- ously or the like in an effective concentration in a physiologically suitable diluent with or without adju ⁇ vant.
- One or more booster injections may be desirable.
- the anti-idiotype method of induction of anti-ET-NANB- virus antibodies can alleviate problems which may be caused by passive administration of anti-ET-NANB-virus antibodies, such as an adverse immune response, and those associated with administration of purified blood components, such as infection with as yet undiscovered viruses.
- the ET-NANB derived proteins of the invention are also intended for use in producing antiserum designed for pre- or post-exposure prophylaxis.
- an ET-NANB protein, or mixture of proteins is formulated with a suitable adjuvant and administered by injection to human volunteers, according to known methods for producing human antisera.
- Antibody response to the injected proteins is monitored, during a several- week period following immunization, by periodic serum sampling to detect the presence an anti- ET-NANB serum antibodies, as described in Section IIA above.
- the antiserum from immunized individuals may be administered as a pre-exposure prophylactic measure for individuals who are at risk of contracting infection.
- the anitserum is also useful in treating an individual post-exposure, analogous to the use of high titer antiserum against hepatitis B virus for post-exposure prophylaxis.
- Monoclonal anti-virus particle antibodies or anti-idiotype antibodies can be produced as follows.
- the spleen or lymphocytes from an immunized animal are removed and immortalized or used to prepare hybridomas by methods known to those skilled in the art.
- a human lymphocyte donor is selected.
- a donor known to be infected with a ET-NANB virus (where infection has been shown for example by the presence of anti-virus antibodies in the blood or by virus culture) may serve as a suitable lymphocyte donor.
- Lymphocytes can be isolated from a peripheral blood sample or spleen cells may be used if the donor is subject to splenectomy.
- Epstein-Barr virus (EBV) can be used to immortalize human lymphocytes or a human fusion partner can be used to produce human-human hybridomas.
- Primary ⁇ n vitro immunization with peptides can also be used in the generation of human monoclonal antibodies.
- Antibodies secreted by the immortalized cells are screened to determine the clones that secrete anti ⁇ bodies of the desired specificity.
- the antibodies For monoclonal anti-virus particle antibodies, the antibodies must bind to ET-NANB virus particles.
- monoclonal anti- idiotype antibodies the antibodies must bind to anti- virus particle antibodies.
- Cells producing antibodies of the desired specificity are selected.
- Enzymes DNAse I and alkaline phosphatase were obtained from Boehringer Mannheim Biochemicals (BMB, Indianapolis, IN); EcoRI, EcoRI methylase, DNA ligase, and DNA Polymerase I, from New England Biolabs (NEB, Beverly MA); and RNase A was obtained from Sigma (St. Louis, MO).
- EcoRI linkers were obtained from NEB; and nitro blue tetrazolium (NBT), 5-bromo-4-chloro-3-indolyl phosphate (BCIP)
- cynos Two cynomolgus monkeys (cynos) were intravenously injected with a 10% suspension of a stool pool obtained from a second-passage cyno (cyno #37) infected with a strain of ET-NANB virus isolated from Burma cases whose stools were positive for ET-NANB, as evidenced by binding of 27-34 nm virus-like particles (VLPs) in the stool to immune serum from a known ET- NANB patient.
- VLPs virus-like particles
- the animals developed elevated levels of alanine aminotransferase (ALT) between 24-36 days after innoculation, and one excreted 27-34 nm VLPs in its bile in the pre-acute phase of infection.
- ALT alanine aminotransferase
- duplex cDNA fragments were blunt-ended with T4 DNA polymerase under standard conditions (Maniatis, p. 118), then extracted with phenol/chloroform and precipitated with ethanol.
- the blunt-ended material was ligated with EcoRI linkers under standard conditions (Maniatis, pp. 396-397) and digested with EcoRI to remove redundant linker ends. Non-ligated linkers were removed by sequential isopropanol precipitation.
- Lambda gtlO phage vector (Huynh) was obtained from Promega Biotec (Madison, WI) . This cloning vector has a unique EcoRI cloning site in the phage cl repressor gene.
- the cDNA fragments from above were introduced into the EcoRI site by mixing 0.5 - 1.0 ug EcoRI-cleaved gtlO, 0.5-3 ⁇ l of the above duplex fragments, 0.5 ⁇ l 10X ligation buffer, 0.5 ⁇ l ligase (200 units), and distilled water to 5 ⁇ l. The mixture was incubated overnight at 14°C, followed by in vitro packaging, according to standard methods (Maniatis, pp. 256-268).
- the packaged phage were used to infect an E__ coli hfl strain, such as strain HG415.
- E. coli, strain C600 hfl, avialable from Promega Biotec, Madison, WI could be used.
- the percentage of recombinant plaques obtained with insertion of the EcoRI-ended fragments was less than 5% by analysis of 20 random plaques.
- the resultant cDNA library was plated and phage were eluted from the selection plates by addition of elution buffer. After DNA extraction from the phage, the DNA was digested with EcoRI to release the heterogeneous insert population, and the DNA fragments were fractionated on agarose to remove phage fragments. The 500-4,000 basepair inserts were isolated and recloned into lambda gtlO as above, and the packaged phage was used to infect E. coli strain HG415. The percentage of successful recombinants was greater than 95%. The phage library was plated on E. coli strain HG415, at about 5,000 plaques/plate, on a total of 8 plates.
- Duplex cDNA fragments from noninfected and ET- NANB-infected cynomolgus monkeys were prepared as in Example 1.
- the cDNA fragments were radiolabeled by random priming, using a random-priming labeling kit obtained from Boehringer-Mannheim (Indianapolis, IN).
- the plated cDNA library from Example 1 was transferred to each of two nitrocellulose filters, and the phage DNA was fixed on the filters by baking, according to standard methods (Maniatis, pp. 320- 323).
- the duplicate filters were hybridized with either infected-source or control cDNA probes from above. Autoradiographs of the filters were examined to identify library clones which hybridized with radiolabeled cDNA probes from infected source only, i.e., did not hybridize with cDNA probes from the non ⁇ infected source. Sixteen such clones, out of a total of about 40,000 clones examined, were identified by this subtraction selection method.
- Each of the sixteen clones was picked and replated at low concentration on an agar plate.
- the clones on each plate were transferred to two nitro ⁇ cellulose as duplicate lifts, and examined for hybrid ⁇ ization to radiolabeled cDNA probes from infected and noninfected sources, as above.
- Clones were selected which showed selective binding for infected-source probes (i.e., binding with infected-source probes and substantially no binding with non-infected-source probes).
- One of the clones which bound selectively to probe from infected source was isolated for further study.
- the selected vector was identified as lambda gtlO-1.1, indicated in Figure 1.
- Example 3 ET-NANB Sequence Clone lambda gtlO-1.1 from Example 2 was digested with EcoRI to release the heterologous insert, which was separated from the vector fragments by gel electrophoresis. The electrophoretic mobility of the fragment was consistent with a 1.33 kb fragment. This fragment, which contained EcoRI ends, was inserted into the EcoRI site of a pTZ-KFl vector, whose construction and properties are described in co-owned U.S. patent application for "Cloning Vector System and Method for Rare Clone Identification", Serial No. 125, 650, filed November 25, 1987.
- this plasmid contains a unique EcoRI site adjacent a T7 polymerase promoter site, and plasmid and phage origins of replication. The sequence immediately adjacent each side of the EcoRI site is known.
- E. coli BB4 bacteria obtained from Stratagene (La Jolla, CA, were transformed with the plasmid.
- Radiolabeled ET-NANB probe was prepared by excising the 1.33 kb insert from the lambda gtlO-1.1 phage in Example 2, separating the fragment by gel electrophoresis, and randomly labeling as above.
- Bacteria transfected with the above pTZ-KFl and containing the desired ET-NANB insert were selected by replica lift and hybridization with the radiolabeled ET-NANB probe, according to methods outlined in Example 2.
- cDNA fragment mixtures from the bile of noninfected and ET-NANB-infected cynomolgus monkeys were prepared as above.
- the cDNA fragments obtained from human stool samples were prepared as follows.
- the cDNA fragment mixtures from infected and non-infected bile source, and from infected and non ⁇ infected human-stool source were each amplified by a novel linker/primer replication method described in co- owned patent application serial number 07/208,512 for "DNA Amplification and Subtraction Technique," filed June 17, 1988. Briefly, the fragments in each sample were blunt-ended with DNA Pol I then extracted with phenol/chloroform and precipitated with ethanol. The blunt-ended material was ligated with linkers having the following sequence: 5 '-GGAATTCGCGGCCGCTCG-3 ' 3 '-TTCCTTAAGCGCCGGCGAGC-5 '
- duplex fragements were digested with Nrul to remove linker dimers, mixed with a primer having the sequence 5'-GGAATTCGCGGCCGCTCG-3' , and then heat denatured and cooled to room temperature to form single-strand DNA/primer complexes.
- the complexes were replicated to form duplex fragments by addition of Thermus aquaticus (Taq) polymerase and all four deoxynucleotides.
- the amplified cDNA sequences were fractionated by agarose gel electrophoresis, using a 2% agarose matrix.
- the filters were hybridized to a random-labeled ⁇ 2 P probe prepared by (i) treating the pTZ-KFl(ETl.l) plasmid from above with EcoRI, (ii) isolating the released 1.33 kb ET-NANB fragment, and (iii) randomly labeling the isolated fragment.
- the probe hybridization was performed by conventional Southern blotting methods (Maniatis, pp. 382-389).
- Figure 2 shows the hybridization pattern obtained with cDNAs from infected (I) and non-infected (N) bile sources (2A) and from infected (I) and non ⁇ infected (N) human stool sources (2B).
- the ET-NANB probe hybridized with fragments obtained from both of the infected sources, but was non-homologous to sequences obtained from either of the non-infected sources, thus confirming the specificity of derived sequence.
- the pTZ-KFl(ETl.l) plasmid from Example 2 was digested with EcoRI to release the 1.33 kb ET-NANB insert which was purified from the linearized plasmid by gel electrophoresis.
- the purified fragment was suspended in a standard digest buffer (0.5M Tris HCl, pH 7.5; 1 mg/ml BSA; lOmM MnCl 2 ) to a concentration of about 1 mg/ml and digested with DNAse I at room temperature for about 5 minutes.
- a standard digest buffer 0.5M Tris HCl, pH 7.5; 1 mg/ml BSA; lOmM MnCl 2
- These reaction conditions were determined from a prior calibration study, in which the incubation time required to produce predominantly 100-300 basepair fragments was determined.
- the material was extracted with phenol/chloroform before ethanol precipitation.
- the fragments in the digest mixture were blunt- ended and ligated with EcoRI linkers as in Example 1.
- the resultant fragments were analyzed by electrophoresis (5-10V/cm) on 1.2% agarose gel, using PhiX174/HaeIII and lambda/HindiII size markers.
- the 100-300 bp fraction was eluted onto NA45 strips (Schleicher and Schuell), which were then placed into 1.5 ml microtubes with eluting solution (1 M NaCl, 50 mM arginine, pH 9.0), and incubated at 67°C for 30-60 minutes.
- the eluted DNA was phenol/chloroform extracted and then precipitated with two volumes of ethanol.
- the pellet was resuspended in 20 ⁇ l TE (0.01 M Tris HCl, pH 7.5, 0.001 M EDTA) .
- Lambda gtll phage vector (Huynh) was obtained from Promega Biotec (Madison, WI). This cloning vector has a unique EcoRI cloning site 53 base pairs upstream from the beta-galactosidase translation termination codon.
- the genomic fragments from above were introduced into the EcoRI site by mixing 0.5-1.0 ⁇ g EcoRI-cleaved gtll, 0.3-3 ⁇ l of the above sized fragments, 0.5 ⁇ l 10X ligation buffer (above), 0.5 ⁇ l ligase (200 units), and distilled water to 5 ⁇ l. The mixture was incubated overnight at 14°C, followed by i ⁇ vitro packaging, according to standard methods (Maniatis, pp. 256-268).
- the packaged phage were used to infect E. coli strain KM392, obtained from Dr. Kevin Moore, DNAX (Palo Alto, CA).
- E. Coli strain Y1090 available from the American Type Culture Collection (ATCC #37197), could be used.
- the infected bacteria were plated and the resultant colonies were checked for loss of beta-galactosidase activity-(clear plaques) in the presence of X-gal using a standard X-gal substrate plaque assay method (Maniatis). About 50% of the phage plaques showed loss of beta-galactosidase enzyme activity (recombinants).
- ET-NANB convalescent antiserum was obtained from patients infected during documented ET-NANB outbreaks in Mexico, Borneo, Pakistan, Somalia, and Burma. The sera were immunoreactive with VLPs in stool specimens from each of several other patients with ET- NANB hepatitis.
- a lawn of E. coli KM392 cells infected with about 10 ⁇ pfu of the phage stock from above was prepared on a 150 mm plate and incubated, inverted, for 5-8 hours at 37°C.
- the lawn was overlaid with a nitrocellulose sheet, causing transfer of expressed ET- NANB recombinant protein from the plaques to the paper.
- the plate and filter were indexed for matching corresponding plate and filter positions.
- the filter was washed twice in TBST buffer (10 mM Tris, pH 8.0, 105 mM NaCl, 0.05% Tween 20), blocked with AIB (TBST buffer with 1% gelatin), washed again in TBST, and incubated overnight after addition of antiserum (diluted to 1:50 in AIB, 12-15 ml/plate).
- the sheet was washed twice in TBST and then contacted with enzyme-labeled anti-human antibody to attach the labeled antibody at filter sites containing antigen recognized by the antiserum.
- the filter was developed in a substrate medium containing 33 ⁇ l NBT (50 mg/ml stock solution maintained at 5°C) mixed with 16 ⁇ l BCIP (50 mg/ml stock solution maintained at 5°C) in 5 ml of alkaline phosphatase buffer (100 mM Tris, 9.5, 100 mM NaCl, 5 mM MgCl 2 ). Purple color appeared at points of antigen production, as recognized by the antiserum.
- ET 13-1 2 101 The coding system for this epitope falls between nucleotide 2 (5'-end) and 101 (3'-end). Genetic sequences related to this short sequence are therefore also preferred, as are peptides produced using this coding region.
Abstract
Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for indentifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, using probe-specific amplification of virus-derived DNA fragments.
Description
ENTERICALLY TRANSMITTED NON-A/NON-B HEPATITIS VIRAL AGENT
CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part of U.S. Application Serial No. 208,997, filed June 17, 1988, which is herein incorporated by reference.
INTRODUCTION
Field of Invention
This invention relates to recombinant proteins, genes, and gene probes and more specifically to such proteins and probes derived from an enterically transmitted nonA/nonB hepatitis viral agent, and to diagnostic methods and vaccine applications which employ the proteins and probes.
Background
Enterically transmitted non-A/non-B (ET-NANB) hepatitis viral agent is the reported cause of hepatitis in several epidemics and sporadic cases in Asia, Africa, and the Indian subcontinent. Infection is usually by water contaminated with feces, although the virus may also spread by close physical contact. The virus does not seem to cause chronic infection.
The viral etiology in ET-NANB has been demonstrated by infection of volunteers with pooled fecal isolates; Immune electron microscopy (IEM) studies have shown virus particles with 27-34 nm diameters in stools from infected individuals. The virus particles reacted with antibodies in serum from infected individuals from geographically distinct regions, suggesting that a
single viral agent or class is responsible for the majority of ET-NANB hepatitis seen worldwide. No antibody reaction was seen in serum from individuals infected with blood-transmitted NANB virus, indicating a different specificity between the two NANB types. In addition to serological differences, the two types of NANB infection show distinct clinical differences. ET-NANB is characteristically an acute infection, often associated with fever and arthralgia, and with portal inflammation and associated bile stasis in liver biopsy specimens (Arankalle). Symptoms are usually resolved within six weeks. Blood-transmitted NANB, by contrast, produces a chronic infection in about 50% of the cases. Fever and arthralgia are rarely seen, and inflammation has a predominantly parenchymal distribution (Khuroo, 1980). The two viral agents can also be distinguished on the basis of primate host susceptibility. ET-NANB, but not the blood-transmitted agent, can be transmitted to cynomolgus monkeys. The blood-transmitted agent is more readily transmitted to chimpanzees than is ET-NANB (Bradley, 1987).
There have been major efforts worldwide to identify and clone viral genomic sequences associated with ET-NANB hepatitis. One goal of this effort, requiring virus-specific genomic sequences, is to identify and characterize the nature of the virus and its protein products. Another goal is to produce recombinant viral proteins which can be used in antibody-based diagnostic procedures and for a vaccine. Despite these efforts, viral sequences associated with ET-NANB hepatitis have not been successfully identified or cloned heretofore, nor have any virus-specific proteins been identified or produced.
Relevant Literature
Arankalle, V.A., et al. , The Lancet, 550 (March 12, 1988) .
Bradley, D.W., et al. , J Gen. Virol. , 69:1 (1988).
Bradley, D.W. et al. , Proc. Nat. Acad. Sci., USA, 84:6277 (1987).
Gravelle, CR. et al. , J. Infect. Diseases, 131:167 (1975). Kane, M.A. , et al., JAMA, 252:3140 (1984).
Khuroo, M.S., Am. J. Med., 48:818 (1980).
Khuroo, M.S., et al. , Am. J. Med. , 68:818 (1983).
Maniatis, T., et al. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (1982).
Seto, B., et al., Lancet, 11:941 (1984).
Sreenivasan, M.A.m et al., J. Gen. Virol. , 65:1005 (1984). Tabor, E., et al., J. Infect. Pis., 140:789
(1979).
SUMMARY OF THE INVENTION Novel compositions, as well as methods of preparation and use of the compositions are provided, where the compositions comprise viral proteins and fragments thereof derived from the viral agent for ET- NANB. Methods for preparation of ET-NANB viral proteins include isolating ET-NANB genomic sequences which are then cloned and expressed in a host cell. The resultant recombinant viral proteins find use as diagnostic agents and as vaccines. The genomic sequences and fragments thereof find use in preparing ET-NANB viral proteins and as probes for virus detection.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows vector constructions and manipulations used in obtaining and sequencing cloned ET-NANB fragment; and Figures 2A-2B are representations of Southern blots in which a radiolabeled ET-NANB probe was hybridized with amplified cDNA fragments prepared from RNA isolated from infected (I) and non-infected (N) bile sources (2A), and from infected (I) and non- infected (N) stool-sample sources (2B).
DESCRIPTION OF SPECIFIC EMBODIMENTS Novel compositions comprising generic sequences and fragments thereof derived from the viral agent for ET-NANB are provided, together with recombinant viral proteins produced using the genomic sequences and methods of using these compositions. The genome of the ET-NANB viral agent is identified as containing a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ- KF1 (ET1.1) carried in E. coli strain BB4 and having ATCC deposit no. 67717. Initial studies sequenced the two terminal regions of the insert and an intermediate region. The 5'-end region of this insert contains the sequence:
1 42
GAT GGA AGG CAC TAA TCT GGC AAG ACC TGT CCC TGT TGC AGC
43 84
TGT TCT ACC ACC CTG CCC CGA GCT CGA ACA GGG CCT TCT CTA
85 126
CCT GCC CCA GGA GCT CAC ACA CCC TGT GAT AGT GTC GTA ACA
127 168
TTT GAA TTA ACA GAC ATT GTG CAC TGC CGC ATG GCC GCC CCG
169 210
AGC CAG CGC AAG GCC GTG CTG TCC ACA CTC GTG GGC CGC TAC
211 GGC.
An intermediate region has the sequence:
691 731
CTA GAG TGT GCT ATT ATG GAG GAG TGT GGG ATG CCG CAG TGG
733 774
CTC ATC CGC CTG TAT CAC CTT ATA AGG TCT GCG TGG ATC TTG
775 816
CAG GCC CCG AAG GAG TCT CTG CGA GGG TTT TGG AAG AAA CAC
817 858 TCC GGT GAG CCC GGC ACT CTT CTA TGG AAT ACT GTC TGG AAT
859 900
ATG GCC GTT ATT ACC CAC TGT TAT GAC TTC CGC GAT TTT CAG
901 942
GTG GCT GCC TTT AAA GGT GAT GAT TCG ATA GTG CTT TGC AGT
943 984
GAG TAT CGT CAG AGT CCA GGA GCT GCT GTC CTG ATC GCC GGC
985 1026
TGT GGC TTG AAG TTG AAG GTA GAT TTC CGC CCG ATC GGT TTG
1027 TAT.
The 3'-end region contains the sequence:
1191 1232
TGA GTA GAG GAT GTT GTT TCC CGT GTT TAT GGG GTT TCC CCT
5
1233 1274
GGA CTC GTT CAT AAC CTG ATT GGC ATG CTA CAG GCT GTT GCT
1275 1316 0 GAT GGC AAG GCA CAT TTC ACT GAG TCA GTA AAA CCA GTG CTC
1317 1327 GAC CGG AAT TC.
5 Additional work has provided the entire sequence, in both directions, as set forth below. The sequence of both strands is provided, since it is not known in which strand the gene is located. However, the sequence in one direction has been designated as the 0 "forward" sequence because of statistical similarities to known proteins. This sequence is set forth below along with the three possible translation sequences. There is one long open reading frame that starts at nucleotide 145 with an isoleucine and extends to the 5 end of the sequence. The two other reading frames have many termination codons. Standard abbreviations for nucleotides and amino acids are used here and elsewhere in this specification.
30 Forward Sequence
R I P P T D G R H Z S G K T C P C C S C
E F R Q L M E G T N L A R P V P V A A V
N S A N Z W K A L I W Q D L S L L Q L F 35 * * * * *
1 11 21 31 41 51 CGAATTCCGCCAACTGATGGAAGGCACTAATCTGGCAAGACCTGTCCCTGTTGCAGCTGT
S T T L P R A R T G P S L P A P G A H H L P P C P E L E Q G L L Y L P Q E L T T Y H P A P S S N R A F S T C P R S S P P
* * * * * *
61 71 81 91 101 111
TCTACCACCCTGCCCCGAGCTCGAACAGGGCCTTCTCTACCTGCCCCAGGAGCTCACCAC
L Z Z C R N I Z I N R H C A L P H G R P C D S V V T F E L T D I V H C R M A A P
V I V S Z H L N Z Q T L C T A A W P P R
* * * * * *
121 131 141 151 161 171
CTGTGATAGTGTCGTAACATTTGAATTAACAGACATTGTGCACTGCCGCATGGCCGCCCC
E P A Q G R A V H T R G P L R R R T K L S Q R K A V L S T L V G R Y G V A Q S S
A S A R P C C P H S W A A T A S H K A L
* * * - * * *
181 191 201 211 221 231
GAGCCAGCGCAAGGCCGTGCTGTCCACACTCGTGGGCCGCTACGGCGTCGCACAAAGCTC
Y N A S H S D V R D S L A R F I P A I G T M L P T L M F A T L S P V L S R P L A
Q C F P L Z C S R L S R P F Y P G H W P
* * * * * *
241 251 261 271 281 291 TACAATGCTTCCCACTCTGATGTTCGCGACTCTCTCGCCCGTTTTATCCCGGCCATTGGC
P V Q V T T C E L Y E L V E A M V E K G P Y R L Q L V N C T S Z W R P W S R R A
R T G Y N L Z I V R A S G G H G R E G P * * * * * *
301 311 321 331 341 351 CCCGTACAGGTTACAACTTGTGAATTGTACGAGCTAGTGGAGGCCATGGTCGAGAAGGGC
Q D G S A V L E L D L C N R D V S R I T R M A P P S L S L I F A T V T C P G S P G W L R R P Z A Z S L Q P Z R V Q D H L * * * * * *
36l' 371 381 391 401 411
CAGGATGGCTCCGCCGTCCTTGAGCTTGATCTTTGCAACCGTGACGTGTCCAGGATCACC
F F Q K D C N K F T T G E T I A H G K V
S S R K I V T S S P Q V R P L P M V K W
L P E R L Z Q V H H R Z D H C P W Z S G * * * * * *
421 431 441 451 461 471
TTCTTCCAGAAAGATTGTAACAAGTTCACCACAGGTGAGACCATTGCCCATGGTAAAGTG
G Q G I S A W S K T F C A L F G P W F R
A R A S R P G A R P S A P S L A L G S A
P G H L G L E Q D L L R P L W P L V P R * - * * * * *
481 491 501 511 521 531
GGCCAGGGCATCTCGGCCTGGAGCAAGACCTTCTGCGCCCTCTTTGGCCCTTGGTTCCGC
A I E K A I L A L L P Q G V F Y G D A F L L R R L F W P C S L R V C F T V M P L Y Z E G Y S G P A P S G C V L R Z C L Z * * * * * *
541 551 561 571 581 591
GCTATTGAGAAGGCTATTCTGGCCCTGCTCCCTCAGGGTGTGTTTTACGGTGATGCCTTT
D D T V F S A A V A A A K A S M V F E N
M T P S S R R L W P Q Q R H P W C L R M
Z H R L L G G C G R S K G I H G V Z E Z * * * * * *
601 611 621 631 641 651
GATGACACCGTCTTCTCGGCGGCTGTGGCCGCAGCAAAGGCATCCATGGTGTTTGAGAAT
D F S E F D S T Q N N F S L G L E C A I
T F L S L T P P R I T F L W V Z S V L L
L F Z V Z L H P E Z L F S G S R V C Y Y * * * * * *
661 ' 671 681 691 701 711
GACTTTTCTGAGTTTGACTCCACCCAGAATAACTTTTCTCTGGGTCTAGAGTGTGCTATT
M E E C G M P Q W L I R L Y H L I R S A W R S V G C R S G S S A C I T L Z G L R G G V W D A A V A H P P V S P Y K V C V * * * * * *
721 731 741 751 761 771
ATGGAGGAGTGTGGGATGCCGCAGTGGCTCATCCGCCTGTATCACCTTATAAGGTCTGCG
W I L Q A P K E S L R G F W K K H S G E G S C R P R R S L C E G F G R N T P V S D L A G P E G V S A R V L E E T L R Z A * * * * * *
781 791 801 811 821 831
TGGATCTTGCAGGCCCCGAAGGAGTCTCTGCGAGGGTTTTGGAAGAAACACTCCGGTGAG
P G T L L W N T V W N M A V I T H C Y D
P A L F Y G I L S G I W P L L P T V M T
R H S S M E Y C L E Y G R Y Y P L L Z L * * * * * *
841 851 861 871 881 891
CCCGGCACTCTTCTATGGAATACTGTCTGGAATATGGCCGTTATTACCCACTGTTATGAC
F R D F Q V A A F K G D D S I V L C S E
S A I F R W L P L K V M I R Z C F A V S
P R F S G G C L Z R Z Z F D S A L Q Z V * * * * * *
901 911 921 931 941 951
TTCCGCGATTTTCAGGTGGCTGCCTTTAAAGGTGATGATTCGATAGTGCTTTGCAGTGAG
Y R Q S P G A A V L I A G C G L K L K V I V R V Q E L L S Z S P A V A Z S Z R Z
S S E S R S C C P D R R L W L E V E G R
* * * * * *
961 971 981 991 1001 1011
TATCGTCAGAGTCCAGGAGCTGCTGTCCTGATCGCCGGCTGTGGCTTGAAGTTGAAGGTA
D F R P I G L Y A G V V V A P G L G A L I S A R S V C M Q V L W W P P A L A R S F P P D R F V C R C C G G P R P W R A P
* * * * * *
1021 1031 1041 1051 1061 1071
GATTTCCGCCCGATCGGTTTGTATGCAGGTGTTGTGGTGGCCCCCGGCCTTGGCGCGCTC
P D V V R F A G R L T E K N W G P G P E L M L C A S P A G L P R R I G A L A L S
Z C C A L R R P A Y R E E L G P P Z A
* * * * * *
1081 1091 1101 1111 1121 1131
CCTGATGTTGTGCGCTTCGCCGGCCGGCTTACCGAGAAGAATTGGGGCCCTGGCCCTGAG
R A E Q L R L A V S D F L . R K L T N V A G R S S S A S L L V I S S A S S R M Z L
G G A A P P R C Z Z F P P Q A H E C S S
* * * * * *
1141 1151 1161 1171 1181 1191
CGGGCGGAGCAGCTCCGCCTCGCTGTTAGTGATTTCCTCCGCAAGCTCACGAATGTAGCT
Q M C V D V V S R V Y G V S P G L V H N R C V W M L F P V F M G F P L D S F I T
D V C G C C F P C L W G F P W T R S Z P
* * * * * *
1201 1211 1221 1231 1241 1251 CAGATGTGTGTGGATGTTGTTTCCCGTGTTTATGGGGTTTCCCCTGGACTCGTTCATAAC
L I G M L Q A V A D G K A H F T E S V K Z L A C Y R L L L M A R H I S L S Q Z N D W H A T G C C Z W Q G T F H Z V S K T
* * * * * *
1261 1271 1281 1291 1301 1311
CTGATTGGCATGCTACAGGCTGTTGCTGATGGCAAGGCACATTTCACTGAGTCAGTAAAA
P V L D R N S S Q C S T G I R S A R P E F E
* * *
1321 1331 1341 CCAGTGCTCGACCGGAATTCGAGC
The complimentary strand, referred to here as the "reverse sequence," is set forth below in the same manner as the forward sequence set forth above. Several open reading frames, shorter than the long open reading frame found in the forward sequence, can be seen in this reverse sequence.
Reverse Sequence
A R I P V E H W F Y Z L S E M C L A I S L E F R S S T G F T D S V K C A L P S A
S N S G R A L V L L T Q Z N V P C H Q Q
* * * * * *
1 11 21 31 41 51
GCTCGAATTCCGGTCGAGCACTGGTTTTACTGACTCAGTGAAATGTGCCTTGCCATCAGC
N S L Z H A N Q V M N E S R G N P I N T T A C S M P I R L Z T S P G E T P Z T R
Q P V A C Q S G Y E R V Q G K P H K H G
* * * * * *
61 71 81 91 101 111
AACAGCCTGTAGCATGCCAATCAGGTTATGAACGAGTCCAGGGGAAACCCCATAAACACG
G N N I H T H L S Y I R E L A E E I T N E T T S T H I Z A T F V S L R R K S L T K Q H P H T S E L H S Z A C G G N H Z Q * * * * * *
121 131 141 151 161 171
GGAAACAACATCCACACACATCTGAGCTACATTCGTGAGCTTGCGGAGGAAATCACTAAC
S E A E L L R P L R A R A P I L L G K P
A R R S C S A R S G P G P Q F F S V S R
R G G A A P P A Q G Q G P N S S R Z A G * * * * * *
181 191 201 211 221 231
AGCGAGGCGGAGCTGCTCCGCCCGCTCAGGGCCAGGGCCCCAATTCTTCTCGGTAAGCCG
A G E A H N I R E R A K A G G H H N T C
P A K R T T S G S A P R P G A T T T P A
R R S A Q H Q G A R Q G R G P P Q H L H * * * * * *
241 251 261 271 281 291
GCCGGCGAAGCGCACAACATCAGGGAGCGCGCCAAGGCCGGGGGCCACCACAACACCTGC
Ϊ Q T D R A E I Y L Q L Q A T A G D Q D
Y K P I G R K S T F N F K P Q P A I R T
T N R S G G N L P S T S S H S R R S G Q * * * * * *
301 311 321 331 341 351
ATACAAACCGATCGGGCGGAAATCTACCTTCAACTTCAAGCCACAGCCGGCGATCAGGAC
S S S W T L T I L T A K H Y R I I T F K
A A P G L Z R Y S L Q S T I E S S P L K
Q L L D S D D T H C K A L S N H H L Z R * * * * * *
361 371 381 391 401 411
AGCAGCTCCTGGACTCTGACGATACTCACTGCAAAGCACTATCGAATCATCACCTTTAAA
G S H L K I A E V I T V G N N G H I P D
A A T Z K S R K S Z Q W V I T A I F Q T
Q P P E N R G S H N S G Z Z R P Y S R Q * * * * * *
421 431 441 451 461 471
GGCAGCCACCTGAAAATCGCGGAAGTCATAACAGTGGGTAATAACGGCCATATTCCAGAC
S I P Z K S A G L T G V F L P K P S Q R V F H R R V P G S P E C F F Q N P R R D Y S I E E C R A H R S V S S K T L A E T * * * * * *
481 491 501 511 521 531
AGTATTCCATAGAAGAGTGCCGGGCTCACCGGAGTGTTTCTTCCAAAACCCTCGCAGAGA
L L R G L Q D P R R P Y K V I Q A D E P
S F G A C K I H A D L I R Z Y R R M S H
P S G P A R S T Q T L Z G D T G G Z A T * * * * * *
541 551 561 571 581 591
CTCCTTCGGGGCCTGCAAGATCCACGCAGACCTTATAAGGTGATACAGGCGGATGAGCCA
L R H P T L L H N S T L Z T Q R K V I L
C G I P H S S I I A H S R P R E K L F W
A A S H T P P Z Z H T L D P E K S Y S G * * * * * *
601 611 621 631 641 651
CTGCGGCATCCCACACTCCTCCATAATAGCACACTCTAGACCCAGAGAAAAGTTATTCTG
G G V K L R K V I L K H H G C L C C G H
V E S N S E K S F S N T M D A F A A A T
W S Q T Q K S H S Q T P W M P L L R P Q * * * * * *
661 671 681 691 701 711
GGTGGAGTCAAACTCAGAAAAGTCATTCTCAAACACCATGGATGCCTTTGCTGCGGCCAC
S R R E D G V I K G I T V K H T L R E Q A A E K T V S S K A S P Z N T P Z G S R
P P R R R C H Q R H H R K T H P E G A G
* * * * * *
721 731 741 751 761 771
AGCCGCCGAGAAGACGGTGTCATCAAAGGCATCACCGTAAAACACACCCTGAGGGAGCAG
G Q N S L L N S A E P R A K E G A E G L A R I A F S I A R N Q G P K R A Q K V L
P E Z P S Q Z R G T K G Q R G R R R S C
* * * * * *
781 791 801 811 821 831
GGCCAGAATAGCCTTCTCAATAGCGCGGAACCAAGGGCCAAAGAGGGCGCAGAAGGTCTT
A P G R D A L A H F T M G N G L T C G E L Q A E M P W P T L P W A M V S P V V N
S R P R C P G P L Y H G Q W S H L W Z T
* * * * * *
841 851 861 871 881 891
GCTCCAGGCCGAGATGCCCTGGCCCACTTTACCATGGGCAATGGTCTCACCTGTGGTGAA
L V T I F L E E G D P G H .V V A K I K L L Q S F W K K V I L D T S R L Q R S S C Y N L S G R R Z S W T R H G C K D Q A
* * * * * *
901 911 921 931 941 951
CTTGTTACAATCTTTCTGGAAGAAGGTGATCCTGGACACGTCACGGTTGCAAAGATCAAG
L K D G G A I L A L L D H G L H Z L V Q S R T A E P S W P F S T M A S T S S Y N
Q G R R S H P G P S R P W P P L A R T I
* * * * * *
961 971 981 991 1001 1011 CTCAAGGACGGCGGAGCCATCCTGGCCCTTCTCGACCATGGCCTCCACTAGCTCGTACAA
F T S C N L Y G A N G R D K T G E R V A S Q V V T C T G P M A G I K R A R E S R H K L Z P V R G Q W P G Z N G R E S R E
* * * * * *
1021 1031 1041 1051 1061 1071
TTCACAAGTTGTAACCTGTACGGGGCCAATGGCCGGGATAAAACGGGCGAGAGAGTCGCG
N I R V G S I V E L C A T P Z R P T S V T S E W E A L Z S F V R R R S G P R V W
H Q S G K H C R A L C D A V A A H E C G
* * * * * *
1081 1091 1101 1111 1121 1131
AACATCAGAGTGGGAAGCATTGTAGAGCTTTGTGCGACGCCGTAGCGGCCCACGAGTGTG
D S T A L R W L G A A M R. Q C T M S V N T A R P C A G S G R P C G S A Q C L L I
Q H G L A L A R G G H A A V H N V C Z F
* * * * * *
1141 1151 1161 1171 1181 1191
GACAGCACGGCCTTGCGCTGGCTCGGGGCGGCCATGCGGCAGTGCACAATGTCTGTTAAT
S N V T T L S Q V V S S W G R Z R R P C Q M L R H Y H R W Z A P G A G R E G P V
K C Y D T I T G G E L L G Q V E K A L F
* * * * * *
1201 1211 1221 1231 1241 1251
TCAAATGTTACGACACTATCACAGGTGGTGAGCTCCTGGGGCAGGTAGAGAAGGCCCTGT
S S S G Q G G R T A A T G T G L A R L V R A R G R V V E Q L Q Q G Q V L P D Z C
E L G A G W Z N S C N R D R S C Q I S A
* * * * * *
1261 1271 1281 1291 1301 1311 TCGAGCTCGGGGCAGGGTGGTAGAACAGCTGCAACAGGGACAGGTCTTGCCAGATTAGTG
P S I S W R N S L P S V G G I F H Q L A E F * * *
1321 1331 1341 CCTTCCATCAGTTGGCGGAATTCG
DETAILED DESCRIPTION OF THE INVENTION
I. Definitions
The terms defined below have the following meaning herein:
1. "Enterically transmitted non-A/non-B (ET-NANB) hepatitis viral agent" means a virus, virus type, or virus class which (1) causes water-borne, infectious hepatitis, (ii) is transmissible in cynomolgus monkeys, (iii) is serologically distinct from hepatitis A virus (ΞAV) and hepatitis B virus (HAB), and (iv) includes a genomic region which is homologous to the 1.33 kb cDNA insert in plasmid pTZ-KFl(ETl.l) carried in E. coli strain BB4 identified by ATCC deposit number 67717.
2. Two double-strand nucleic acid fragments are "homologous" if their opposite strands are capable of hybridizing to one another under moderately stringent hybridization conditions, i.e., where hybridized strands contain at most about 5-10% basepair mismatches. A single-strand nucleic acid species is homologous to a double-strand fragment if it contains a region which is capable of hybridizing to one of the fragment strands under moderately stringent hybridization conditions.
3. A DNA fragment is "derived from" an ET-NANB viral agent if it has the same or substantially the
same basepair sequence as a region of the viral agent genome.
4. A protein is "derived from" an ET-NANB viral agent if it is encoded by an open reading frame of a DNA or RNA fragment derived from an ET-NANB viral agent.
II. Obtaining Cloned ET-NANB Fragments
According to one aspect of the invention, it has been found that a virus-specific DNA clone can be produced by (a) isolating RNA from the bile of a cynomolgus monkey having a known ET-NANB infection, (b) cloning the cDNA fragments to form a fragment library, and (c) screening the library by differential hybridization to radiolabeled cDNAs from infected and non-infected bile sources.
A. cDNA Fragment Mixture
ET-NANB infection in cynomolgus monkeys is initiated by inoculating the animals intravenously with a 10% w/v suspension from human case stools positive for 27-34 nm ET-NANB particles (mean diameter 32 nm) . An infected animal is monitored for elevated levels of alanine aminotransferase, indicating hepatitis infection. ET-NANB infection is confirmed by immunospecific binding of seropositive antibodies to virus-like particles (VLPs), according to published methods (Gravelle). Briefly, a stool (or bile) specimen taken from the infected animal 3-4 weeks after infection is diluted 1:10 with phosphate-buffered saline, and the 10% suspension is clarified by low- speed centrifugation and filtration successively through 1.2 and 0.45 micron filters. The material may be further purified by pelleting through a 30% sucrose cushion (Bradley). The resulting preparation of VLPs is mixed with diluted serum from human patients with known ET-NANB infection. After incubation overnight,
the mixture is centrifuged overnight to pellet immune aggregates, and these are stained and examined by electron microscopy for antibody binding to the VLPs. ET-NANB infection can also be confirmed by seroconversion to VLP-positive serum. Here the serum of the infected animal is mixed as above with 27-34 nm VLPs isolated form the stool specimens of infected human cases and examined by immune electron microscopy for antibody binding to the VLPs. Bile can be collected from ET-NANB positive animals by either cannulating the bile duct and collecting the bile fluid or by draining the bile duct during necropsy. Total RNA is extracted from the bile by hot phenol extraction, as outlined in Example IA. The RNA fragments are used to synthesize corresponding duplex cDNA fragments by random priming, also as referenced in Example IA. The cDNA fragments may be fractionated by gel electrophoresis or density gradient centrifugation to obtain a desired size class of fragments, e.g., 500-4,000 basepair fragments.
Although alternative sources of viral material, such as VLPs obtained from stool samples (as described in Example 4), may be used for producing a cDNA fraction, the bile source is preferred. According to one aspect of the invention, it has been found that bile from ET-NANB-infected monkeys shows a greater number of intact viral particles than material obtained from stool samples, as evidenced by immune electron microscopy. Bile obtained from an ET-NANB infected human or cynomolgus monkey, for use as a source of ET- NANB viral protein or genomic material, or intact virus, forms part of the present invention.
B. cDNA Library and Screening The cDNA fragments from above are cloned into a suitable cloning vector to form a cDNA library. This may be done by equipping blunt-ended fragments with a
suitable end linker, such as an EcoRI sequence, and inserting the fragments into a suitable insertion site of a cloning vector, such as at a unique EcoRI site. After initial cloning, the library may be recloned, if desired, to increase the percentage of vectors containing a fragment insert. The library construction described in Example IB is illustrative. Here cDNA fragments were blunt-ended, equipped with EcoRI ends, and inserted into the EcoRI site of the lambda phage vector gtlO. The library phage, which showed less than 5% fragment inserts, was isolated, and the fragment inserts recloned into the lambda gtlO vector, yielding more than 95% insert-containing phage.
The cDNA library is screened for sequences specific for ET-NANB by differential hybridization to cDNA probes derived from infected and non-infected sources. cDNA fragments from infected and non-infected source bile or stool viral isolates can be prepared as above. Radiolabeling the fragments is by random labeling, nick translation, or end labeling, according to conventional methods (Maniatis, p. 109). The cDNA library from above is screened by transfer to duplicate nitrocellulose filters, and hybridization with both infected-source and non-infected-source (control) radiolabeled probes, as detailed in Example 2. Plaques which show selective hybridization to the infected- source probes are preferably replated at low plating density and rescreened as above, to isolate single clones which are specific for ET-NANB sequences. As indicated in Example 2, sixteen clones which hybridized specifically with infected-source probes were indentified by these procedures. One of the clones, designated lambda gtlO-1.1, contained a 1.33 kilobase fragment insert.
C. ET-NANB Sequences
The basepair sequence of cloned regions of the
ET-NANB fragments from Part B are determined by standard sequencing methods. In one illustrative method, described in Example 3, the fragment insert from the selected cloning vector is excised, isolated by gel electrophoresis, and inserted into a cloning vector whose basepair sequence on either side of the insertion site is known. The particular vector employed in Example 3 is a pTZ-KFl vector shown at the left in Figure 1. The ET-NANB fragment from the gtlO- 1.1 phage was inserted at the unique EcoRI site of the pTZ-KFl plasmid. Recombinants carrying the desired insert were identified by hybridization with the isolated 1.33 kilobase fragment, as described in Example 3. One selected plasmid, identified as pTZ-KFl (ET1.1), gave the expected 1.33 kb fragment after vector digestion with EcoRI. E. coli strain BB4 infected with the pTZ-KFl(ETl.l) plasmid has been deposited with the American Type Culture Collection, Rockville, MD, and is identified by ATCC deposit nubmer 67717.
The pTZ-KFl(ETl.l) plasmid is illustrated at the bottom in Figure 1. The fragment insert has 5' and 3' end regions denoted at A and C, respectively, and an intermediate region, denoted at B. The sequences in these regions were determined by standard dideoxy sequencing and are set forth above. The three short sequences (A, B, and C) are from the same insert strand. As will be seen in Example 3, the B-region sequence was actually determined from the opposite strand, so that the B-region sequence shown above represent the complement of the sequence in the sequenced strand. The base numbers of the partial sequences are approximate.
Later work in the laboratory of the inventors identified the full sequence, also set forth above. Fragments of this total sequence can readily be prepared using restriction endonucleases. Computer
analysis of both the forward and reverse sequence has identified a number of cleavage sites. The specific cleavage sites are summarized (for the forward direction) in the following tables.
Pattern identifier Pattern matched Base number matched (Λ = cleavage site) in "forward" strand
CC'WGG(BstNI) CO/JGG 106, 360, 410, 483
497, 973, 1129, 1243
CCΛSGG(NciI) CCSGG 288, 841, 1063 GAAGANNNNNNNN~(MboII) GAAGA 822, 1116 TCTTC(<-7-MbθII) TCTTC 422, . 611, 849 GCGTC(<-10-Hgal) GCGTC 225 GCATCNNNNN*(SfaNI) GCATC 488, 640 GCAGCNNNNNNNN (Bbvl) GCAGC 53, 631, 1149 GCTGC(<-12-Bbvl) GCTGC 919, 979 GGATGNNNNNNNNN"(Fokl) GGATG 363, 734, 1212 CATCC(<-13-F0kI) CATCC 641, 750 GGTGANNNNNNNN"(HphI) GGTGA 454, 589, 835, 931 TCACC(<-7-HphI) TCACC 114, 416, 446, 762 GPΛCGYC(AhaII) GPCGYC 224 GDGCHΛC(BspI1286) GDGCHC 77, 110, 158, 838, 1125, 1324
GPGCYΛC(BanII) GPGCYC 77, 110, 838, 1125
CΛYCGPG(AvaI) CYCGPG 74, 178
YΛGGCCP(EaeI) YGGCCP 171, 290, 626, 875, 1101
GWGCVTC ( GgiAI ) GWGCWC 77, 110, 158, 1324
C CTTGG(StyI) CCTTGG 529, 1068
PΛGATCY(XhoII) PGATCY 782
CAGΛCTG(PvuII) CAGCTG 54
CΛCATGG(NcoI) CCATGG 344, 468, 644
CGATΛCG(PvuI) CGATCG 1031
CΛGGCCG(EagI) CGGCCG 1101
G AATTC(EcoRI) GAATTC 2, 1335
GAGCTΛC(SacI) GAGCTC 77, 110
GCATGΛC(SphI) GCATGC 1268
GCC~GGC(NaeI) GCCGGC 994, 1099, 1103
GΛCGCGC(BssHII) GCGCGC 1073
GGGCC~C(ApaI) GGGCCC 1125
TCGΛCGA(NruI) TCGCGA 264
TACTAGA(XbaI) TCTAGA 705
TTT~AAA(DraI) TTTAAA 925
GATGCAC(ApaLI) GTGCAC 158
ACCTGCNNNN~(BpsMI) ACCTGC 99
GCAGG (<-8-BspMI) GCAGGT 1045
GACNΛNNGTC(Tthllll) GACNNNGTC 604
CCANNNN"NTGG(Pf1MI) CCANNNNNTGG 10
CCΛTNAGG(MstII) CCTNAGG 571
GCCNNNNΛNGGC(BglI) GCCNNNNNGGC 216, 359, 738
CCANNNNN'NTGG(BstXI) CCANNNNNNTGG 204
III. ET-NANB Fragments
According to another aspect, the invention includes ET-NANB-specific fragments or probes which hybridize with ET-NANB genomic sequences or cDNA fragments derived therefrom. The fragments may include full-length cDNA fragments such as described in Section II, or may be derived from shorter sequence regions within cloned cDNA fragments. Shorter fragments can be prepared by enzymatic digestion of full-length fragments under conditions which yield desired-sized fragments, as will be described in Section IV. Alternatively, the fragments can be produced by oligonucleotide synthetic methods, using sequences derived from the cDNA fragments. Methods or services for producing selected-sequence oligonucleotide fragments are available.
To confirm that a given ET-NANB fragment is in fact derived from the ET-NANB viral agent, the fragment
can be shown to hybridize selectively with cDNA from infected sources. By way of illustration, to confirm that the 1.33 kb fragment in the pTZ-KFl(El.l) plasmid is ET-NANB in origin, the fragment was excised from the pTZ-KFl(ETl.l) plasmid, purified, and radiolabeled by random labeling. The radiolabeled fragment was hybridized with fractionated cDNAs from infected and non-infected sources to confirm that the probe reacts only with infected-source cDNAs. This method is illustrated in Example 4, where the above radiolabeled 1.33 kb fragment from pTZ-KFl(ETl.l) plasmid was examined for binding to cDNAs prepared from infected and non-infected sources. The infected sources are (1) bile from a cynomolgus monkey infected with a strain of virus derived from stool samples from human patients from Burma with known ET-NANB infections and (2) a viral agent derived from the stool sample of a human ET-NANB patient from Mexico. The cDNAs in each fragment mixture were first amplified by a linker/primer amplification method described in Example 4. Fragment separation was on agarose gel, followed by Southern blotting and then hybridization to bind the radiolabeled 1.33 kb fragment to the fractionated cDNAs. The lane containing cDNAs from the infected sources showed a smeared band of bound probe, as expected (cDNAs amplified by the linker/primer amplification method would be expected to have a broad range of sizes). No probe binding to the amplified cDNAs from the non-infected sources was observed. The results indicate that the 1.33 kb probe is specific for cDNA fragments associated with ET-NANB infection. This same type of study, using ET 1.1 as the probe, has demonstrated hybridization to ET-NANB samples collected from Tashkent, Somalia, Borneo and Pakistan. Secondly, the fact that the probe is specific for ET-NANB related sequences derived from different continents (Asia, Africa and North America) indicates the cloned ET-NANB
Africa sequence is derived from a common ET-NANB virus or virus class responsible for ET-NANB hepatitis infection worldwide.
In a related confirmatory study, probe binding to fractionated genomic fragments prepared from human or cynomolgus monkey genomic DNA was examined. No probe binding was observed to either genomic fraction, demonstrating that the ET-NANB fragment is not an endogenous human or cynomologus fragment. Another confirmation of ET-NANB specific sequences in the fragments is the ability to express ET-NANB proteins from coding regions in the fragments. Section IV below discusses methods of protein expression using the fragments. One important use of the ET-NANB-specific fragments is for identifying ET-NANB-derived cDNAs which contain additional sequence information. The newly identified cDNAs, in turn, yield new fragment probes, allowing further iterations until the entire viral genome is identified and sequenced. Procedures for identifying additional ET-NANB library clones and generating new probes therefrom generally follow the cloning and selection procedures described in Section II. The fragments (and oligonucleotides prepared based on the sequences given above) are also useful as primers for a poly erase chain reaction method of detecting ET-NANB viral genomic material in a patient sample. This diagnostic method will be described in Section V below.
IV. ET-NANB Proteins
As indicated above, ET-NANB proteins can be prepared by expressing open reading-frame coding regions in ET-NANB fragments. In one preferred approach, the ET-NANB fragments used for protein
expression are derived from cloned cDNAs which have been treated to produce desired-size fragments, and preferably random fragments with sizes predominantly between about 100 to about 300 base pairs. Example 5 describes the preparation of such fragments by DNAs digestion. Because it is desired to obtain peptide antigens of between about 30 to about 100 amino acids, the digest fragments are preferably size fractionated, for example by gel electrophoresis, to select those in the approximately 100-300 basepair size range.
A. Expression Vector
The ET-NANB fragments are inserted into a suitable expression vector. One exemplary expression vector is lambda gtll, which contains a unique EcoRI insertion site 53 base pairs upstream of the translation termination codon of the beta-galactosidase gene. Thus, the inserted sequence will be expressed as a beta-galactosidase fusion protein which contains the N-terminal portion of the beta-galactosidase gene, the heterologous peptide, and optionally the C-terminal region of the beta-galactosidase peptide (the C- terminal portion being expressed when the heterologous peptide coding sequence does not contain a translation termination codon). This vector also produces a temperature-sensitive repressor (cl857) which causes viral lysogeny at permissive temperatures, e.g., 32°C, and leads to viral lysis at elevated temperatures, e.g., 42°C. Advantages of this vector include: (1) highly efficient recombinant generation, (2) ability to select lysogenized host cells on the basis of host-cell growth at permissive, but not non-permissive, temperatures, and (3) high levels of recombinant fusion protein production. Further, since phage containing a heterologous insert produces an inactive beta- galactosidase enzyme, phage with inserts can be readily identified by a beta-galactosidase colored-substrate
reaction.
For insertion into the expression vector, the viral digest fragments may be modified, if needed, to contain selected restriction-site linkers, such as EcoRI linkers, according to conventional procedures. Example 1 illustrates methods for cloning the digest fragments into lambda gtll, which includes the steps of blunt-ending the fragments, ligating with EcoRI linkers, and introducing the fragments into EcoRI-cut lambda gtll. The resulting viral genomic library may be checked to confirm that a relatively large (representative) library has been produced. This can be done, in the case of the lambda gtll vector, by infecting a suitable bacterial host, plating the bacteria, and examining the plaques for loss of beta- galactosidase activity. Using the procedures described in Example 1, about 50% of the plaques showed loss of enzyme activity.
B. Peptide Antigen Expression
The viral genomic library formed above is screened for production of peptide antigen (expressed as a fusion protein) which is immunoreactive with antiserum from ET-NANB seropositive individuals. In a preferred screening method, host cells infected with phage library vectors are plated, as above, and the plate is blotted with a nitrocellulose filter to transfer recombinant protein antigens produced by the cells onto the filter. The filter is then reacted with the ET-NANB antiserum, washed to remove unbound antibody, and reacted with reporter-labeled, anti-human antibody, which becomes bound to the filter, in sandwich fashion, through the anti-ET-NANB antibody. Typically phage plaques which are identified by virtue of their production of recombinant antigen of interest are re-examined at a relatively low density for production of antibody-reactive fusion protein.
Several recombinant phage clones which produced immunoreactive recombinant antigen were identified in the procedure.
The selected expression vectors may be used for scale-up production, for purposes of recombinant protein purification. Scale-up production is carried out using one of a variety of reported methods for (a) lysogenizing a suitable host, such as E. coli, with a selected lambda gtll recombinant (b) culturing the transduced cells under conditions that yield high levels of the heterologous peptide, and (c) purifying the recombinant antigen from the lysed cells.
In one preferred method involving the above lambda gtll cloning vector, a high-producer E. coli host, BNN103, is infected with the selected library phage and replica plated on two plates. One of the plates is grown at 32βC, at which viral lysogeny can occur, and the other at 42°C, at which the infecting phage is in a lytic stage and therefore prevents cell growth. Cells which grow at the lower but not the higher temperature are therefore assumed to be successfully lysogenized.
The lysogenized host cells are then grown under liquid culture conditions which favor high production of the fused protein containing the viral insert, and lysed by rapid freezing to release the desired fusion protein.
C. Peptide Purification The recombinant peptide can be purified by standard protein purification procedures which may include differential precipitation, molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis and affinity chromatography. In the case of a fused protein, such as the beta-galactosidase fused protein prepared as above, the protein isolation techniques which are used
can be adapted from those used in isolation of the native protein. Thus, for isolation of a beta- glactosidase fusion protein, the protein can be isolated readily by simple affinity chromatography, by passing the cell lysis material over a solid support having surface-bound anti-beta-galactosidase antibody.
D. Viral Proteins
The ET-NANB protein of the invention may also be derived directly from the ET-NANB viral agent. VLPs isolated from a stool sample from an infected individual, as above, are one suitable source of viral protein material. The VLPs isolated from the stool sample may be further purified by affinity chromatography prior to protein isolation (see below). The viral agent may also be raised in cell culture, which provides a convenient and potentially concentrated source of viral protein. Co-owned U.S. Patent Application Serial No. 846,757, filed April 1, 1986, describes an immortalized trioma liver cell which supports NANB infection in cell culture. The trioma cell line is prepared by fusing human liver cells with a mouse/human fusion partner selected for human chromosome stability. Cells containing the desired NANB viral agent can be identified by immuno- fluorescence methods, employing anti-ET-NANB human antibodies.
The viral agent is disrupted, prior to protein isolation, by conventional methods, which can include sonication, high- or low-salt conditions, or use of detergents.
Purification of ET-NANB viral protein can be carried out by affinity chromatography, using a purified anti-ET-NANB antibody attached according to standard methods to a suitable solid support. The antibody itself may be purified by affinity chromatography, where an immunoreactive recombinant ET-
NANB protein, such as described above, is attached to a solid support, for isolation of anti-ET-NANB antibodies from an immune serum source. The bound antibody is released from the support by standard methods. Alternatively, the anti-ET-NANB antibody may be a monoclonal antibody (Mab) prepared by immunizing a mouse or other animal with recombinant ET-NANB protein, isolating lymphocytes from the animal and immortalizing the cells with a suitable fusion partner, and selecting successful fusion products which react with the recombinant protein immunogen. These in turn may be used in affinity purification procedures, described above, to obtain native ET-NANB antigen.
V. Utility
A. Diagnostic Methods
The particles and antigens of the invention, as well as the genetic material, can be used in diagnostic assays. Methods for detecting the presence of ET-NANB hepatitis comprise analyzing a biological sample such as a blood sample, stool sample or liver biopsy specimen for the presence of an analyte associated with ET-NANB hepatitis virus. The analyte can be a nucleotide sequence which hybridizes with a probe comprising a sequence of at least about 16 consecutive nucleotides, usually 30 to 200 nucleotides, up to substantially the full sequence of the sequences shown above (cDNA sequences). The analyte can be RNA or cDNA. The analyte is typically a virus particle suspected of being ET-NANB or a particle for which this classification is being ruled out. The virus particle can be further characterized as having an RNA viral genome comprising a sequence at least about 80% homologous to a sequence of at least 12 consecutive nucleotides of the "forward" and "reverse" sequences given above, usually at least about 90%
homologous to at least about 60 consecutive nucleotides within the sequences, and may comprise a sequence substantially homologous to the full-length sequences. In order to detect an analyte, where the analyte hybridizes to a probe, the probe may contain a detectable label.
The analyte can also comprise an antibody which recognizes an antigen, such as a cell surface antigen, on a ET-NANB virus particle. The analyte can also be a ET-NANB viral antigen. Where the analyte is an antibody or an antigen, either a labelled antigen or antibody, respectively, can be used to bind to the analyte to form an immunological complex, which can then be detected by means of the label. Typically, methods for detecting analytes such as surface antigens and/or whole particles are based on i munoassays. I munoassays can be conducted either to determine the presence"of antibodies in the host that have arisen from infection by ET-NANB hepatitis virus or by assays that directly determine the presence of virus particles or antigens. Such techniques are well known and need not be described here in detail. Exam¬ ples include both heterogeneous and homogeneous immuno- assay techniques. Both techniques are based on the formation of an immunological complex between the virus particle or its antigen and a corresponding specific antibody. Heterogeneous assays for viral antigens typically use a specific monoclonal or polyclonal antibody bound to a solid surface. Sandwich assays are becoming increasingly popular. Homogeneous assays, which are carried out in solution without the presence of a solid phase, can also be used, for example by determining the difference in enzyme activity brought on by binding of free antibody to an enzyme-antigen conjugate. A number of suitable assays are disclosed
in U.S. Patent Nos. 3,817,837, 4,006,360, 3,996,345. When assaying for the presence of antibodies induced by ET-NANB viruses, the viruses and antigens of the invention can be used as specific binding agents to detect either IgG or IgM antibodies. Since IgM anti¬ bodies are typically the first antibodies that appear during the course of an infection, when IgG synthesis may not yet have been initiated, specifically distin¬ guishing between IgM and IgG antibodies present in the blood stream of a host will enable a physician or other investigator to determine whether the infection is recent or chronic.
In one diagnostic configuration, test serum is reacted with a solid phase reagent having surface-bound ET-NANB protein antigen. After binding anti-ET-NANB antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-ET-NANB antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric or colorimetric substrate.
The solid surface reagent in the above assay prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activate carboxyl, hydroxyl, or aldehyde group.
In a second diagnostic configuration, known as
a homogeneous assay, antibody binding to a solid support produces some change in the reaction medium which can be directly detected in the medium. Known general types of homogeneous assays proposed heretofore include (a) spin-labeled reporters, where antibody binding to the antigen is detected by a change in reported mobility (broadening of the spin splitting peaks), (b) fluorescent reporters, where binding is detected by a change in fluorescence efficiency, (c) enzyme reporters, where antibody binding effects enzyme/substrate interactions, and (d) liposome-bound reporters, where binding leads to liposome lysis and release of encapsulated reporter. The adaptation of these methods to the protein antigen of the present invention follows conventional methods for preparing homogeneous assay reagents.
In each of the assays described above, the assay method involves reacting the serum from a test individual with the protein antigen and examining the antigen for the presence of bound antibody. The examining may involve attaching a labeled anti-human antibody to the antibody being examined, either IgM (acute phase) or IgG (convalescent phase), and measuring the amount of reporter bound to the solid support, as in the first method, or may involve observing the effect of antibody binding on a homogeneous assay reagent, as in the second method.
Also forming part of the invention is an assay system or kit for carrying out the assay method just described. The kit generally includes a support with surface-bound recombinant protein antigen which is (a) immunoreactive with antibodies present in individuals infected with enterically transmitted nonA/nonB viral agent and (b) derived from a viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ- KFl(ETl.l) carried in E. Coli strain BB4, and having
ATCC deposit no. 67717. A reporter-labeled anti-human antibody in the kit is used for detecting surface-bound anti-ET-NANB antibody.
B. Viral Genome Diagnostic Applications
The genetic material of the invention can it¬ self be used in numerous assays as probes for genetic material present in naturally occurring infections. One method for amplification of target nucleic acids, for later analysis by hybridization assays, is known as the polymerase chain reaction or PCR technique. The PCR technique can be applied to detecting virus particles of the invention in suspected pathological samples using oligonucleotide primers spaced apart from each other and based on the genetic sequence set forth above. The primers are complementary to opposite strands of a double stranded DNA molecule and are typically separated by from about 50 to 450 nt or more (usually not more than 2000 nt). This method entails preparing the specific oligonucleotide primers and then repeated cycles of target DNA denaturation, primer binding, and extension with a DNA polymerase to obtain DNA fragments of the expected length based on the primer spacing. Extension products generated from one primer serve as additional target sequences for the other primer. The degree of amplification of a target sequence is controlled by the number of cycles that are performed and is theoretically calculated by the simple formula 2n where n is the number of cycles. Given that the average efficiency per cycle ranges from about 65% to 85%, 25 cycles produce from 0.3 to 4.8 million copies of the target sequence. The PCR method is de¬ scribed in a number of publications, including Saiki e_t §!•» Science (1985) 23_0:1350-1354; Saiki et al. , Nature (1986) 3_24_:163-166; and Scharf et al. , Science (1986) 2_3_3:1076-1078. Also see U.S. Patent Nos. 4,683,194; 4,683,195; and 4,683,202.
The invention includes a specific diagnostic method for determination of ET-NANB viral agent, based on selective amplification of ET-NANB fragments. This method employs a pair of single-strand primers derived from non-homologous regions of opposite strands of a DNA duplex fragment, which in turn is derived from an enterically transmitted viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ- KFl(ETl.l) carried in E. coli strain BB4, and having ATCC deposit no. 67717. These "primer fragments," which form one aspect of the invention, are prepared f om ET-NANB fragments such as described in Section III above. The method follows the process for amplifying selected nucleic acid sequences as disclosed in U.S. Patent No. 4,683,202, as discussed above.
C. Peptide Vaccine
Any of the antigens of the invention can be used in preparation of a vaccine. A preferred starting material for preparation of a vaccine is the particle antigen isolated from bile. The antigens are preferably initially recovered as intact particles as described above. However, it is also possible to pre- pare a suitable vaccine from particles isolated from other sources or non-particle recombinant antigens. When non-particle antigens are used (typically soluble antigens), proteins derived from the viral envelope or viral capsid are preferred for use in preparing vac- cines. These proteins can be purified by affinity chromatography, also described above.
If the purified protein is not immunogenic per se, it can be bound to a carrier to make the protein immunogenic. Carriers include bovine serum albumin, keyhole limpet hemocyanin and the like. It is desir¬ able, but not necessary, to purify antigens to be sub¬ stantially free of human protein. However, it is more
important that the antigens be free of proteins, viruses, and other substances not of human origin that may have been introduced by way of, or contamination of, the nutrient medium, cell lines, tissues, or patho- logical fluids from which the virus is cultured or obtained.
Vaccination can be conducted in conventional fashion. For example, the antigen, whether a viral particle or a protein, can be used in a suitable diluent such as water, saline, buffered salines, complete or incomplete adjuvants, and the like. The immunogen is administered using standard techniques for antibody induction, such as by subcutaneous administra¬ tion of physiologically compatible, sterile solutions containing inactivated or attenuated virus particles or antigens. An immune response producing amount of virus particles is typically administered per vaccinizing injection, typically in a volume of one milliliter or less. A specific example of a vaccine composition includes, in a pharmacologically acceptable adjuvant, a recombinant protein or protein mixture derived from- an enterically transmitted nonA/nonB viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ- KFl(ETl.l) carried in E. coli strain BB4, and having ATCC deposit no. 67717. The vaccine is administered at periodic intervals until a significant titer of anti- ET-NANB antibody is detected in the serum. The vaccine is intended to protect against ET-NANB infection.
D. Prophylactic and Therapeutic Antibodies and Antisera
In addition to use as a vaccine, the composi- tions can be used to prepare antibodies to ET-NANB virus particles. The antibodies can be used directly as antiviral agents. To prepare antibodies, a host
animal is immunized using the virus particles or, as appropriate, non-particle antigens native to the virus particle are bound to a carrier as described above for vaccines. The host serum or plasma is collected following an appropriate time interval to provide a composition comprising antibodies reactive with the virus particle. The gamma globulin fraction or the IgG antibodies can be obtained, for example, by use of saturated ammonium sulfate or DEAE Sephadex, or other techniques known to those skilled in the art. The antibodies are substantially free of many of the adverse side effects which may be associated with other anti-viral agents such as drugs.
The antibody compositions can be made even more compatible with the host system by minimizing potential adverse immune system responses. This is accomplished by removing all or a portion of the Fc portion of a foreign species antibody or using an antibody of the same species as the host animal, for example, the use of antibodies from human/human hybridomas.
The antibodies can also be used as a means of enhancing the immune response since antibody-virus complexes are recognized by macrophages. The anti¬ bodies can be administered in amounts similar to those used for other therapeutic administrations of anti¬ body. For example, pooled gamma globulin is admini¬ stered at 0.02-0.1 ml/lb body weight during the early incubation of other viral diseases such as rabies, measles and hepatitis B to interfere with viral entry into cells. Thus, antibodies reactive with the ET-NANB virus particle can be passively administered alone or in conjunction with another anti-viral agent to a host infected with an ET-NANB virus to enhance the immune response and/or the effectiveness of an antiviral drug. Alternatively, anti-ET-NANB-virus antibodies can be induced by administering anti-idiotype anti¬ bodies as immunogens. Conveniently, a purified anti-
ET-NANB-virus antibody preparation prepared as descibed above is used to induce anti-idiotype antibody in a host animal. The composition is administered to the host animal in a suitable diluent. Following administration, usually repeated administration, the host produces anti-idiotype antibody. To eliminate an immunogenic response to the Fc region, antibodies pro¬ duced by the same species as the host animal can be used or the Fc region of the administered antibodies can be removed. Following induction of anti-idiotype antibody in the host animal, serum or plasma is removed to provide an antibody composition. The composition can be purified as described above for anti-ET-NANB- virus antibodies, or by affinity chromatography using anti-ET-NANB-virus antibodies bound to the affinity matrix. The anti-idiotype antibodies produced are similar in conformation to the authentic ET-NANB antigen and may be used to prepare an ET-NANB vaccine rather than using a ET-NANB particle antigen. When used as a means of inducing anti-ET-NANB- virus antibodies in a patient, the manner of injecting the antibody is the same as for vaccination purposes, namely intramuscularly, intraperitoneally, subcutane- ously or the like in an effective concentration in a physiologically suitable diluent with or without adju¬ vant. One or more booster injections may be desirable. The anti-idiotype method of induction of anti-ET-NANB- virus antibodies can alleviate problems which may be caused by passive administration of anti-ET-NANB-virus antibodies, such as an adverse immune response, and those associated with administration of purified blood components, such as infection with as yet undiscovered viruses.
The ET-NANB derived proteins of the invention are also intended for use in producing antiserum designed for pre- or post-exposure prophylaxis. Here an ET-NANB protein, or mixture of proteins is
formulated with a suitable adjuvant and administered by injection to human volunteers, according to known methods for producing human antisera. Antibody response to the injected proteins is monitored, during a several- week period following immunization, by periodic serum sampling to detect the presence an anti- ET-NANB serum antibodies, as described in Section IIA above.
The antiserum from immunized individuals may be administered as a pre-exposure prophylactic measure for individuals who are at risk of contracting infection. The anitserum is also useful in treating an individual post-exposure, analogous to the use of high titer antiserum against hepatitis B virus for post-exposure prophylaxis.
E. Monoclonal Antibodies
For both jji vivo use of antibodies to ET-NANB virus particles and proteins and anti-idiotype anti- bodies and diagnostic use, it may be preferable to use monoclonal antibodies. Monoclonal anti-virus particle antibodies or anti-idiotype antibodies can be produced as follows. The spleen or lymphocytes from an immunized animal are removed and immortalized or used to prepare hybridomas by methods known to those skilled in the art. To produce a human-human hybridoma, a human lymphocyte donor is selected. A donor known to be infected with a ET-NANB virus (where infection has been shown for example by the presence of anti-virus antibodies in the blood or by virus culture) may serve as a suitable lymphocyte donor. Lymphocytes can be isolated from a peripheral blood sample or spleen cells may be used if the donor is subject to splenectomy. Epstein-Barr virus (EBV) can be used to immortalize human lymphocytes or a human fusion partner can be used to produce human-human hybridomas. Primary ^n vitro immunization with peptides can also be used in the
generation of human monoclonal antibodies.
Antibodies secreted by the immortalized cells are screened to determine the clones that secrete anti¬ bodies of the desired specificity. For monoclonal anti-virus particle antibodies, the antibodies must bind to ET-NANB virus particles. For monoclonal anti- idiotype antibodies, the antibodies must bind to anti- virus particle antibodies. Cells producing antibodies of the desired specificity are selected. The following examples illustrate various aspects of the invention, but are in no way intended to limit the scope thereof.
Material The materials used in the following Examples were as follows:
Enzymes: DNAse I and alkaline phosphatase were obtained from Boehringer Mannheim Biochemicals (BMB, Indianapolis, IN); EcoRI, EcoRI methylase, DNA ligase, and DNA Polymerase I, from New England Biolabs (NEB, Beverly MA); and RNase A was obtained from Sigma (St. Louis, MO).
Other reagents: EcoRI linkers were obtained from NEB; and nitro blue tetrazolium (NBT), 5-bromo-4-chloro-3-indolyl phosphate (BCIP)
5-bromo-4-chloro-3-indolyl-B-D-galactopyranoside (X- gal) and isopropyl B-D-thiogalactopyranoside (IPTG) were obtained from Sigma. cDNA synthesis kit and random priming labeling kits are available from Boehringer-Mannheim Biochemical (BMB, Indianapolis, IN).
Eample 1 Preparing cDNA Library
A. Source of ET-NANB virus
Two cynomolgus monkeys (cynos) were
intravenously injected with a 10% suspension of a stool pool obtained from a second-passage cyno (cyno #37) infected with a strain of ET-NANB virus isolated from Burma cases whose stools were positive for ET-NANB, as evidenced by binding of 27-34 nm virus-like particles (VLPs) in the stool to immune serum from a known ET- NANB patient. The animals developed elevated levels of alanine aminotransferase (ALT) between 24-36 days after innoculation, and one excreted 27-34 nm VLPs in its bile in the pre-acute phase of infection.
The bile duct of each infected animal was cannulated and about 1-3 cc of bile was collected daily. RNA was extracted from one bile specimen (cyno #121) by hot phenol extraction, using a standard RNA isolation procedure. Double-strand cDNA was formed from the isolated RNA by a random primer for first- strand generation, using a cDNA synthesis kit obtained from Boehringer-Mannheim (Indianapolis, IN).
B. Cloning the Duplex Fragments
The duplex cDNA fragments were blunt-ended with T4 DNA polymerase under standard conditions (Maniatis, p. 118), then extracted with phenol/chloroform and precipitated with ethanol. The blunt-ended material was ligated with EcoRI linkers under standard conditions (Maniatis, pp. 396-397) and digested with EcoRI to remove redundant linker ends. Non-ligated linkers were removed by sequential isopropanol precipitation. Lambda gtlO phage vector (Huynh) was obtained from Promega Biotec (Madison, WI) . This cloning vector has a unique EcoRI cloning site in the phage cl repressor gene. The cDNA fragments from above were introduced into the EcoRI site by mixing 0.5 - 1.0 ug EcoRI-cleaved gtlO, 0.5-3 μl of the above duplex fragments, 0.5 μl 10X ligation buffer, 0.5 μl ligase (200 units), and distilled water to 5 μl. The mixture
was incubated overnight at 14°C, followed by in vitro packaging, according to standard methods (Maniatis, pp. 256-268).
The packaged phage were used to infect an E__ coli hfl strain, such as strain HG415. Alternatively, E. coli, strain C600 hfl, avialable from Promega Biotec, Madison, WI, could be used. The percentage of recombinant plaques obtained with insertion of the EcoRI-ended fragments was less than 5% by analysis of 20 random plaques.
The resultant cDNA library was plated and phage were eluted from the selection plates by addition of elution buffer. After DNA extraction from the phage, the DNA was digested with EcoRI to release the heterogeneous insert population, and the DNA fragments were fractionated on agarose to remove phage fragments. The 500-4,000 basepair inserts were isolated and recloned into lambda gtlO as above, and the packaged phage was used to infect E. coli strain HG415. The percentage of successful recombinants was greater than 95%. The phage library was plated on E. coli strain HG415, at about 5,000 plaques/plate, on a total of 8 plates.
Example 2 Selecting ET-NANB Cloned Fragments A. cDNA Probes
Duplex cDNA fragments from noninfected and ET- NANB-infected cynomolgus monkeys were prepared as in Example 1. The cDNA fragments were radiolabeled by random priming, using a random-priming labeling kit obtained from Boehringer-Mannheim (Indianapolis, IN).
B. Clone Selection
The plated cDNA library from Example 1 was transferred to each of two nitrocellulose filters, and the phage DNA was fixed on the filters by baking, according to standard methods (Maniatis, pp. 320- 323). The duplicate filters were hybridized with either infected-source or control cDNA probes from above. Autoradiographs of the filters were examined to identify library clones which hybridized with radiolabeled cDNA probes from infected source only, i.e., did not hybridize with cDNA probes from the non¬ infected source. Sixteen such clones, out of a total of about 40,000 clones examined, were identified by this subtraction selection method.
Each of the sixteen clones was picked and replated at low concentration on an agar plate. The clones on each plate were transferred to two nitro¬ cellulose as duplicate lifts, and examined for hybrid¬ ization to radiolabeled cDNA probes from infected and noninfected sources, as above. Clones were selected which showed selective binding for infected-source probes (i.e., binding with infected-source probes and substantially no binding with non-infected-source probes). One of the clones which bound selectively to probe from infected source was isolated for further study. The selected vector was identified as lambda gtlO-1.1, indicated in Figure 1.
Example 3 ET-NANB Sequence Clone lambda gtlO-1.1 from Example 2 was digested with EcoRI to release the heterologous insert, which was separated from the vector fragments by gel electrophoresis. The electrophoretic mobility of the fragment was consistent with a 1.33 kb fragment. This fragment, which contained EcoRI ends, was inserted into the EcoRI site of a pTZ-KFl vector, whose construction and properties are described in co-owned U.S. patent application for "Cloning Vector System and Method for Rare Clone Identification", Serial No. 125, 650, filed November 25, 1987. Briefly, and as illustrated in Figure 1, this plasmid contains a unique EcoRI site adjacent a T7 polymerase promoter site, and plasmid and phage origins of replication. The sequence immediately adjacent each side of the EcoRI site is known. E. coli BB4 bacteria, obtained from Stratagene (La Jolla, CA, were transformed with the plasmid. Radiolabeled ET-NANB probe was prepared by excising the 1.33 kb insert from the lambda gtlO-1.1 phage in Example 2, separating the fragment by gel electrophoresis, and randomly labeling as above. Bacteria transfected with the above pTZ-KFl and containing the desired ET-NANB insert were selected by replica lift and hybridization with the radiolabeled ET-NANB probe, according to methods outlined in Example 2.
One bacterial colony containing a successsful recombinant was used for sequencing a portion of the 1.33 kb insert. This isolate, designated pTZ- KFl(ETl.l), has been deposited with the American Type Culture Collection, and is identified by ATCC deposit no. 67717. Using a standard dideoxy sequencing procedure, and primers for the sequences flanking the EcoRI site, about 200-250 basepairs of sequence from the 5 '-end region and 3'-end region of the insert were
obtained. The sequences are given above in Section II. Later sequencing by the same techniques gave the full sequence in both directions, also given above.
Example 4
Detecting ET-NANB Sequences cDNA fragment mixtures from the bile of noninfected and ET-NANB-infected cynomolgus monkeys were prepared as above. The cDNA fragments obtained from human stool samples were prepared as follows.
Thirty ml of a 10% stool suspension obtained from an individual from Mexico diagnosed as infected with ET- NANB as a result of an ET-NANB outbreak, and a similar volume of stool from a healthy, non-infected individual, were layered over a 30% sucrose density gradient cushion, and centrifuged at 25,000 xg for 6 hr in an SW27 rotor, at 15°C. The pelleted material from the infected-source stool contained 27-34 nm VLP particles characteristic of ET-NANB infection in the infected-stool sample. RNA was isolated from the sucrose-gradient pellets in both the infected and non¬ infected samples, and the isolated RNA was used to produce cDNA fragments as described in Example 1.
The cDNA fragment mixtures from infected and non-infected bile source, and from infected and non¬ infected human-stool source were each amplified by a novel linker/primer replication method described in co- owned patent application serial number 07/208,512 for "DNA Amplification and Subtraction Technique," filed June 17, 1988. Briefly, the fragments in each sample were blunt-ended with DNA Pol I then extracted with phenol/chloroform and precipitated with ethanol. The blunt-ended material was ligated with linkers having the following sequence:
5 '-GGAATTCGCGGCCGCTCG-3 ' 3 '-TTCCTTAAGCGCCGGCGAGC-5 '
The duplex fragements were digested with Nrul to remove linker dimers, mixed with a primer having the sequence 5'-GGAATTCGCGGCCGCTCG-3' , and then heat denatured and cooled to room temperature to form single-strand DNA/primer complexes. The complexes were replicated to form duplex fragments by addition of Thermus aquaticus (Taq) polymerase and all four deoxynucleotides. The replication procedures, involving successive strand denaturation, formation of strand/primer complexes, and replication, was repeated 25 times. The amplified cDNA sequences were fractionated by agarose gel electrophoresis, using a 2% agarose matrix. After transfer of the DNA fragments from the agarose gels to nitrocellulose paper, the filters were hybridized to a random-labeled ^2P probe prepared by (i) treating the pTZ-KFl(ETl.l) plasmid from above with EcoRI, (ii) isolating the released 1.33 kb ET-NANB fragment, and (iii) randomly labeling the isolated fragment. The probe hybridization was performed by conventional Southern blotting methods (Maniatis, pp. 382-389). Figure 2 shows the hybridization pattern obtained with cDNAs from infected (I) and non-infected (N) bile sources (2A) and from infected (I) and non¬ infected (N) human stool sources (2B). As seen, the ET-NANB probe hybridized with fragments obtained from both of the infected sources, but was non-homologous to sequences obtained from either of the non-infected sources, thus confirming the specificity of derived sequence.
Southern blots of the radiolabeled 1.33 kb fragment with genomic DNA fragments from both human and cynomologus-monkey DNA were also prepared. No probe hybridization to either of the genomic fragment
mixtures was observed, confirming that the ET-NANB sequence is exogenous to either human or cynomolgus genome.
Example 5
Expressing ET-NANB Proteins
A. Preparing ET-NANB Coding Sequences
The pTZ-KFl(ETl.l) plasmid from Example 2 was digested with EcoRI to release the 1.33 kb ET-NANB insert which was purified from the linearized plasmid by gel electrophoresis. The purified fragment was suspended in a standard digest buffer (0.5M Tris HCl, pH 7.5; 1 mg/ml BSA; lOmM MnCl2) to a concentration of about 1 mg/ml and digested with DNAse I at room temperature for about 5 minutes. These reaction conditions were determined from a prior calibration study, in which the incubation time required to produce predominantly 100-300 basepair fragments was determined. The material was extracted with phenol/chloroform before ethanol precipitation.
The fragments in the digest mixture were blunt- ended and ligated with EcoRI linkers as in Example 1. The resultant fragments were analyzed by electrophoresis (5-10V/cm) on 1.2% agarose gel, using PhiX174/HaeIII and lambda/HindiII size markers. The 100-300 bp fraction was eluted onto NA45 strips (Schleicher and Schuell), which were then placed into 1.5 ml microtubes with eluting solution (1 M NaCl, 50 mM arginine, pH 9.0), and incubated at 67°C for 30-60 minutes. The eluted DNA was phenol/chloroform extracted and then precipitated with two volumes of ethanol. The pellet was resuspended in 20 μl TE (0.01 M Tris HCl, pH 7.5, 0.001 M EDTA) .
B. Cloning in an Expression Vector
Lambda gtll phage vector (Huynh) was obtained
from Promega Biotec (Madison, WI). This cloning vector has a unique EcoRI cloning site 53 base pairs upstream from the beta-galactosidase translation termination codon. The genomic fragments from above were introduced into the EcoRI site by mixing 0.5-1.0 μg EcoRI-cleaved gtll, 0.3-3 μl of the above sized fragments, 0.5 μl 10X ligation buffer (above), 0.5 μl ligase (200 units), and distilled water to 5 μl. The mixture was incubated overnight at 14°C, followed by iτ\ vitro packaging, according to standard methods (Maniatis, pp. 256-268).
The packaged phage were used to infect E. coli strain KM392, obtained from Dr. Kevin Moore, DNAX (Palo Alto, CA). Alternatively, E. Coli strain Y1090, available from the American Type Culture Collection (ATCC #37197), could be used. The infected bacteria were plated and the resultant colonies were checked for loss of beta-galactosidase activity-(clear plaques) in the presence of X-gal using a standard X-gal substrate plaque assay method (Maniatis). About 50% of the phage plaques showed loss of beta-galactosidase enzyme activity (recombinants).
C. Screening for ET-NANB Recombinant Proteins ET-NANB convalescent antiserum was obtained from patients infected during documented ET-NANB outbreaks in Mexico, Borneo, Pakistan, Somalia, and Burma. The sera were immunoreactive with VLPs in stool specimens from each of several other patients with ET- NANB hepatitis.
A lawn of E. coli KM392 cells infected with about 10^ pfu of the phage stock from above was prepared on a 150 mm plate and incubated, inverted, for 5-8 hours at 37°C. The lawn was overlaid with a nitrocellulose sheet, causing transfer of expressed ET- NANB recombinant protein from the plaques to the paper. The plate and filter were indexed for matching
corresponding plate and filter positions.
The filter was washed twice in TBST buffer (10 mM Tris, pH 8.0, 105 mM NaCl, 0.05% Tween 20), blocked with AIB (TBST buffer with 1% gelatin), washed again in TBST, and incubated overnight after addition of antiserum (diluted to 1:50 in AIB, 12-15 ml/plate). The sheet was washed twice in TBST and then contacted with enzyme-labeled anti-human antibody to attach the labeled antibody at filter sites containing antigen recognized by the antiserum. After a final washing, the filter was developed in a substrate medium containing 33 μl NBT (50 mg/ml stock solution maintained at 5°C) mixed with 16 μl BCIP (50 mg/ml stock solution maintained at 5°C) in 5 ml of alkaline phosphatase buffer (100 mM Tris, 9.5, 100 mM NaCl, 5 mM MgCl2). Purple color appeared at points of antigen production, as recognized by the antiserum.
D. Screening Plating The areas of antigen production determined in the previous step were replated at about 100-200 pfu on an 82 mm plate. The above steps, beginning with a 5-8 hour incubation, through NBT-BCIP development, were repeated in order to plaque purify phage secreting an antigen capable of reacting with the ET-NANB antibody. The identified plaques were picked and eluted in phage buffer (Maniatis, p. 443).
E. Epitope Identification A series of subclones derived from the original pTZ-KFl (ET1.1) plasmid from Example 2 were isolated using the same techniques described above. Each of these five subclones were immunoreactive with a pool of anti-ET antisera noted in C. The subclones contained short sequences from the "reverse" sequence set forth previously. The beginning and ending points of the sequences in the subclones (relative to the full
"reverse" sequence), are identified in the table below.
TABLE 1
Subclone Position in "Reverse" Sequence
5'-end 3'-end
Yl 522 643
Y2 594 667
Y3 508 665
Y4 558 752
Y5 545 665
Since all of the gene sequences identified in the table must contain the coding sequence for the epitope, it is apparent that the coding sequence for the epitope falls in the region between nucleotide 594 (5'-end) and 643 (3'-end). Genetic sequences equivalent to and complementary to this relatively short sequence are therefore particularly preferred aspects of the present invention, as are peptides produced using this coding region.
A second series of clones identifying an altogether different epitope was isolated with only Mexican serum.
TABLE 2
Subclone Position in "Forward" Sequence
5'end 3' end
ET 2-2 2 193
ET 8-3 2 135
ET 9-1 2 109
ET 13-1 2 101
The coding system for this epitope falls between nucleotide 2 (5'-end) and 101 (3'-end). Genetic sequences related to this short sequence are therefore also preferred, as are peptides produced using this coding region.
While the invention has been described with reference to particular embodiments, methods, construction and use, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the invention.
Claims
1. A protein derived from an enterically transmitted non-A/non-B viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ- KFl(ETl.l) carried in E. coli strain BB4 and having ATCC deposit no. 67717.
2. The protein of claim 1, which is encoded by a coding region within said 1.33 kb EcoRI insert.
3. A recombinant protein derived from an enterically transmitted nonA/nonB viral hepatitis agent whose genome contains a region which is homologous to a duplex DNA having a first sequence:
1 11 21 31 41 51 * * * * * * CGAATTCCGCCAACTGATGGAAGGCACTAATCTGGCAAGACCTGTCCCTGTTGCAGCTGT
61 71 81 91 101 111 * * * * * *
TCTACCACCCTGCCCCGAGCTCGAACAGGGCCTTCTCTACCTGCCCCAGGAGCTCACCAC
121 131 141 151 161 171 * * * * * *
CTGTGATAGTGTCGTAACATTTGAATTAACAGACATTGTGCACTGCCGCATGGCCGCCCC
181 191 201 211 221 231 * * * * * *
GAGCCAGCGCAAGGCCGTGCTGTCCACACTCGTGGGCCGCTACGGCGTCGCACAAAGCTC
241 251 261 271 281 291 * * * * * *
TACAATGCTTCCCACTCTGATGTTCGCGACTCTCTCGCCCGTTTTATCCCGGCCATTGGC
301 311 321 331 341 351 * * * * * *
CCCGTACAGGTTACAACTTGTGAATTGTACGAGCTAGTGGAGGCCATGGTCGAGAAGGGC
361 371 381 391 401 411
* * * * * * CAGGATGGCTCCGCCGTCCTTGAGCTTGATCTTTGCAACCGTGACGTGTCCAGGATCACC
421 431 441 451 461 471 * * * * * *
TTCTTCCAGAAAGATTGTAACAAGTTCACCACAGGTGAGACCATTGCCCATGGTAAAGTG
481 491 501 511 521 531 * * * * * *
GGCCAGGGCATCTCGGCCTGGAGCAAGACCTTCTGCGCCCTCTTTGGCCCTTGGTTCCGC
541 551 561 571 581 591
* * * * * *
GCTATTGAGAAGGCTATTCTGGCCCTGCTCCCTCAGGGTGTGTTTTACGGTGATGCCTTT
601 611 621 631 641 651 * * * * * *
GATGACACCGTCTTCTCGGCGGCTGTGGCCGCAGCAAAGGCATCCATGGTGTTTGAGAAT
661 671 681 691 701 711 * * * * * * GACTTTTCTGAGTTTGACTCCACCCAGAATAACTTTTCTCTGGGTCTAGAGTGTGCTATT 721 731 741 751 761 771 * * * * * *
ATGGAGGAGTGTGGGATGCCGCAGTGGCTCATCCGCCTGTATCACCTTATAAGGTCTGCG
781 791 801 811 821 831 * * * * * *
TGGATCTTGCAGGCCCCGAAGGAGTCTCTGCGAGGGTTTTGGAAGAAACACTCCGGTGAG
841 851 861 871 881 891 * * * * * *
CCCGGCACTCTTCTATGGAATACTGTCTGGAATATGGCCGTTATTACCCACTGTTATGAC
901 911 921 931 941 951 * * * * * * TTCCGCGATTTTCAGGTGGCTGCCTTTAAAGGTGATGATTCGATAGTGCTTTGCAGTGAG
961 971 981 991 1001 1011 * * * * * *
TATCGTCAGAGTCCAGGAGCTGCTGTCCTGATCGCCGGCTGTGGCTTGAAGTTGAAGGTA
1021 1031 1041 1051 1061 1071 * * * * * *
GATTTCCGCCCGATCGGTTTGTATGCAGGTGTTGTGGTGGCCCCCGGCCTTGGCGCGCTC
1081 1091 1101 1111 1121 1131 * * * * * *
CCTGATGTTGTGCGCTTCGCCGGCCGGCTTACCGAGAAGAATTGGGGCCCTGGCCCTGAG
1141 1151 1161 1171 1181 1191 * * * * * *
CGGGCGGAGCAGCTCCGCCTCGCTGTTAGTGATTTCCTCCGCAAGCTCACGAATGTAGCT
1201 1211 1221 1231 1241 1251 * * * * * * CAGATGTGTGTGGATGTTGTTTCCCGTGTTTATGGGGTTTCCCCTGGACTCGTTCATAAC 1261 1271 1281 1291 1301 1311
* * * * * *
CTGATTGGCATGCTACAGGCTGTTGCTGATGGCAAGGCACATTTCACTGAGTCAGTAAAA
1321 1331 1341
* * *
CCAGTGCTCGACCGGAATTCGAGC
or a second sequence
1 11 21 31 41 51
* * * * * *
GCTCGAATTCCGGTCGAGCACTGGTTTTACTGACTCAGTGAAATGTGCCTTGCCATCAGC
61 71 81 91 101 111
* * * * * *
AACAGCCTGTAGCATGCCAATCAGGTTATGAACGAGTCCAGGGGAAACCCCATAAACACG
121 131 141 151 161 171 * * * * * *
GGAAACAACATCCACACACATCTGAGCTACATTCGTGAGCTTGCGGAGGAAATCACTAAC
181 191 201 211 221 231
* * * * * * AGCGAGGCGGAGCTGCTCCGCCCGCTCAGGGCCAGGGCCCCAATTCTTCTCGGTAAGCCG
241 251 261 271 281 291
* * * * * *
GCCGGCGAAGCGCACAACATCAGGGAGCGCGCCAAGGCCGGGGGCCACCACAACACCTGC
301 311 321 331 341 351
* * * * * *
ATACAAACCGATCGGGCGGAAATCTACCTTCAACTTCAAGCCACAGCCGGCGATCAGGAC
361 371 381 391 401 411
* * * * * *
AGCAGCTCCTGGACTCTGACGATACTCACTGCAAAGCACTATCGAATCATCACCTTTAAA 421 431 441 451 461 471 * * * * * *
GGCAGCCACCTGAAAATCGCGGAAGTCATAACAGTGGGTAATAACGGCCATATTCCAGAC
481 491 501 511 521 531 * * * * * *
AGTATTCCATAGAAGAGTGCCGGGCTCACCGGAGTGTTTCTTCCAAAACCCTCGCAGAGA
541 551 561 571 581 591 * * * * * *
CTCCTTCGGGGCCTGCAAGATCCACGCAGACCTTATAAGGTGATACAGGCGGATGAGCCA
601 611 621 631 641 651 * * * * * *
CTGCGGCATCCCACACTCCTCCATAATAGCACACTCTAGACCCAGAGAAAAGTTATTCTG
661 671 681 691 701 711
* * - * * * * GGTGGAGTCAAACTCAGAAAAGTCATTCTCAAACACCATGGATGCCTTTGCTGCGGCCAC
721 731 741 751 761 771 * * * * * *
AGCCGCCGAGAAGACGGTGTCATCAAAGGCATCACCGTAAAACACACCCTGAGGGAGCAG
781 791 801 811 821 831 * * * * * *
GGCCAGAATAGCCTTCTCAATAGCGCGGAACCAAGGGCCAAAGAGGGCGCAGAAGGTCTT
841 851 861 871 881 891
* * * * * *
GCTCCAGGCCGAGATGCCCTGGCCCACTTTACCATGGGCAATGGTCTCACCTGTGGTGAA
901 911 921 931 941 951 * * * * * *
CTTGTTACAATCTTTCTGGAAGAAGGTGATCCTGGACACGTCACGGTTGCAAAGATCAAG 961 971 981 991 1001 1011 * * * * * *
CTCAAGGACGGCGGAGCCATCCTGGCCCTTCTCGACCATGGCCTCCACTAGCTCGTACAA
1021 1031 1041 1051 1061 1071 * * * * * *
TTCACAAGTTGTAACCTGTACGGGGCCAATGGCCGGGATAAAACGGGCGAGAGAGTCGCG
1081 1091 1101 1111 1121 1131 * * * * * *
AACATCAGAGTGGGAAGCATTGTAGAGCTTTGTGCGACGCCGTAGCGGCCCACGAGTGTG
1141 1151 1161 1171 1181 1191 * * * * * * GACAGCACGGCCTTGCGCTGGCTCGGGGCGGCCATGCGGCAGTGCACAATGTCTGTTAAT
1201 1211 1221 1231 1241 1251 * * * * * *
TCAAATGTTACGACACTATCACAGGTGGTGAGCTCCTGGGGCAGGTAGAGAAGGCCCTGT
1261 1271 1281 1291 1301 1311 * * * * * *
TCGAGCTCGGGGCAGGGTGGTAGAACAGCTGCAACAGGGACAGGTCTTGCCAGATTAGTG
1321 1331 1341 * * *
CCTTCCATCAGTTGGCGGAATTCG.
4. A protein which is (a) immunoreactive with antibodies present in individuals infected with enterically transmitted nonA/nonB and (b) derived from a viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ-KFl(ETl.l) carried in E. coli strain BB4, and having ATCC deposit no. 67717.
5. The protein of claim 4, which is encoded by a coding region within said 1.33 kb EcoRI insert.
6. A method of detecting infection by enterically transmitted nonA/nonB hepatitis viral agent in a test individual, comprising: providing a peptide antigen which is (a) immunoreactive with antibodies present in individuals infected with enterically transmitted nonA/nonB hepatitis and (b) derived from a viral hepatitis agent whose genome contains a region which is homlogous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ- KFl(ETl.l) carried in E. coli strain BB4, and having ATCC deposit no. 67717, reacting serum from the test individual with such antigen, and examining the antigen for the presence of bound antibody.
7. The method of claim 6, wherein the serum antibody is an IgM or IgG antibody, or a mixture of both, the antigen provided is attached to a support, said reacting includes contacting such serum with the support and said examining includes reacting the support and bound serum antibody with a reporter-labeled anti-human antibody.
8. A kit for ascertaining the presence of serum antibodies which are diagnostic of enterically transmitted nonA/nonB hepatitis infection, comprising a support with surface-bound recombinant peptide antigen which is (a) immunoreactive with antibodies present in individuals infected with enterically transmitted nonA/nonB viral hepatitis agent and (b) derived from a viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ-KFl(ET1.1) carried in E. coli strain BB4, and having ATCC deposit no. 67717 , a reporter-labeled anti-human antibody.
9. A DNA fragment derived from an enterically transmitted nonA/nonB viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ-KFl(ETl.l) carried in E. coli strain BB4 and having ATCC deposit no. 67717.
10. The fragment of claim 9, which is derived from said 1.33 kb EcoRI insert.
11. A DNA fragment derived from an enterically transmitted nonA/nonB viral hepatitis agent whose genome contains a region which is homologous to a duplex DNA fragment within a first sequence:
1 11 21 31 41 51 * * * * * *
CGAATTCCGCCAACTGATGGAAGGCACTAATCTGGCAAGACCTGTCCCTGTTGCAGCTGT
61 71 81 91 101 111 * * * * * *
TCTACCACCCTGCCCCGAGCTCGAACAGGGCCTTCTCTACCTGCCCCAGGAGCTCACCAC
121 131 141 151 161 171 * * * * * *
CTGTGATAGTGTCGTAACATTTGAATTAACAGACATTGTGCACTGCCGCATGGCCGCCCC
181 191 201 211 221 231 * * * * * *
GAGCCAGCGCAAGGCCGTGCTGTCCACACTCGTGGGCCGCTACGGCGTCGCACAAAGCTC
241 251 261 271 281 291 * * * * * * TACAATGCTTCCCACTCTGATGTTCGCGACTCTCTCGCCCGTTTTATCCCGGCCATTGGC 301 311 321 331 341 351 * * * * * *
CCCGTACAGGTTACAACTTGTGAATTGTACGAGCTAGTGGAGGCCATGGTCGAGAAGGGC
361 371 381 391 401 411 * * * * * *
CAGGATGGCTCCGCCGTCCTTGAGCTTGATCTTTGCAACCGTGACGTGTCCAGGATCACC
421 431 441 451 461 471 * * * * * *
TTCTTCCAGAAAGATTGTAACAAGTTCACCACAGGTGAGACCATTGCCCATGGTAAAGTG
481 491 501 511 521 531 * * * * * *
GGCCAGGGCATCTCGGCCTGGAGCAAGACCTTCTGCGCCCTCTTTGGCCCTTGGTTCCGC
541 551 561 571 581 591 * * ' * . * * * GCTATTGAGAAGGCTATTCTGGCCCTGCTCCCTCAGGGTGTGTTTTACGGTGATGCCTTT
601 611 621 631 641 651 * * * * * *
GATGACACCGTCTTCTCGGCGGCTGTGGCCGCAGCAAAGGCATCCATGGTGTTTGAGAAT
661 671 681 691 701 711 * * * * * *
GACTTTTCTGAGTTTGACTCCACCCAGAATAACTTTTCTCTGGGTCTAGAGTGTGCTATT
721 731 741 751 761 771 * * * * * *
ATGGAGGAGTGTGGGATGCCGCAGTGGCTCATCCGCCTGTATCACCTTATAAGGTCTGCG
781 791 801 811 821 831 * * * * * *
TGGATCTTGCAGGCCCCGAAGGAGTCTCTGCGAGGGTTTTGGAAGAAACACTCCGGTGAG 841 851 861 871 881 891 * * * * * *
CCCGGCACTCTTCTATGGAATACTGTCTGGAATATGGCCGTTATTACCCACTGTTATGAC
901 911 921 931 941 951 * * * * * *
TTCCGCGATTTTCAGGTGGCTGCCTTTAAAGGTGATGATTCGATAGTGCTTTGCAGTGAG
961 971 981 991 1001 1011 * * * * * *
TATCGTCAGAGTCCAGGAGCTGCTGTCCTGATCGCCGGCTGTGGCTTGAAGTTGAAGGTA
1021 1031 1041 1051 1061 1071 * * * * * * GATTTCCGCCCGATCGGTTTGTATGCAGGTGTTGTGGTGGCCCCCGGCCTTGGCGCGCTC
1081 1091 1101 1111 1121 1131 * * * * * *
CCTGATGTTGTGCGCTTCGCCGGCCGGCTTACCGAGAAGAATTGGGGCCCTGGCCCTGAG
1141 1151 1161 1171 1181 1191 * * * * * *
CGGGCGGAGCAGCTCCGCCTCGCTGTTAGTGATTTCCTCCGCAAGCTCACGAATGTAGCT
1201 1211 1221 1231 1241 1251
* * * * * *
CAGATGTGTGTGGATGTTGTTTCCCGTGTTTATGGGGTTTCCCCTGGACTCGTTCATAAC
1261 1271 1281 1291 1301 1311 * * * * * *
CTGATTGGCATGCTACAGGCTGTTGCTGATGGCAAGGCACATTTCACTGAGTCAGTAAAA
1321 1331 1341
* * * CCAGTGCTCGACCGGAATTCGAGC
or a second sequence 1 11 21 31 41 51 * * * * * *
GCTCGAATTCCGGTCGAGCACTGGTTTTACTGACTCAGTGAAATGTGCCTTGCCATCAGC
61 71 81 91 101 111 * * * * * *
AACAGCCTGTAGCATGCCAATCAGGTTATGAACGAGTCCAGGGGAAACCCCATAAACACG
121 131 141 151 161 171 * * * * * *
GGAAACAACATCCACACACATCTGAGCTACATTCGTGAGCTTGCGGAGGAAATCACTAAC
181 191 201 211 221 231 * * * * * *
AGCGAGGCGGAGCTGCTCCGCCCGCTCAGGGCCAGGGCCCCAATTCTTCTCGGTAAGCCG
241 251 261 271 281 291 * * * * * * GCCGGCGAAGCGCACAACATCAGGGAGCGCGCCAAGGCCGGGGGCCACCACAACACCTGC
301 311 321 331 341 351 * * * * * *
ATACAAACCGATCGGGCGGAAATCTACCTTCAACTTCAAGCCACAGCCGGCGATCAGGAC
361 371 381 391 401 411 * * * * * *
AGCAGCTCCTGGACTCTGACGATACTCACTGCAAAGCACTATCGAATCATCACCTTTAAA
421 431 441 451 461 471 * * * * * *
GGCAGCCACCTGAAAATCGCGGAAGTCATAACAGTGGGTAATAACGGCCATATTCCAGAC
481 491 501 511 521 531 * * * * * *
AGTATTCCATAGAAGAGTGCCGGGCTCACCGGAGTGTTTCTTCCAAAACCCTCGCAGAGA 541 551 561 571 581 591
* * * * * *
CTCCTTCGGGGCCTGCAAGATCCACGCAGACCTTATAAGGTGATACAGGCGGATGAGCCA
601 611 621 631 641 651
* * * * * *
CTGCGGCATCCCACACTCCTCCATAATAGCACACTCTAGACCCAGAGAAAAGTTATTCTG
661 671 681 691 701 711 * * * * * *
GGTGGAGTCAAACTCAGAAAAGTCATTCTCAAACACCATGGATGCCTTTGCTGCGGCCAC
721 731 741 751 761 771
* * * * * * AGCCGCCGAGAAGACGGTGTCATCAAAGGCATCACCGTAAAACACACCCTGAGGGAGCAG
781 791 801 811 821 831
* * * * * *
GGCCAGAATAGCCTTCTCAATAGCGCGGAACCAAGGGCCAAAGAGGGCGCAGAAGGTCTT
841 851 861 871 881 891
* * * *. * *
GCTCCAGGCCGAGATGCCCTGGCCCACTTTACCATGGGCAATGGTCTCACCTGTGGTGAA
901 911 921 931 941 951
* * * * * *
CTTGTTACAATCTTTCTGGAAGAAGGTGATCCTGGACACGTCACGGTTGCAAAGATCAAG
961 971 981 991 1001 1011 * * * * * *
CTCAAGGACGGCGGAGCCATCCTGGCCCTTCTCGACCATGGCCTCCACTAGCTCGTACAA
1021 1031 1041 1051 1061 1071
* * * * * * TTCACAAGTTGTAACCTGTACGGGGCCAATGGCCGGGATAAAACGGGCGAGAGAGTCGCG 1081 1091 1101 1111 1121 1131 * * * * * *
AACATCAGAGTGGGAAGCATTGTAGAGCTTTGTGCGACGCCGTAGCGGCCCACGAGTGTG
1141 1151 1161 1171 1181 1191
* * * * * *
GACAGCACGGCCTTGCGCTGGCTCGGGGCGGCCATGCGGCAGTGCACAATGTCTGTTAAT
1201 1211 1221 1231 1241 1251 * * * * * *
TCAAATGTTACGACACTATCACAGGTGGTGAGCTCCTGGGGCAGGTAGAGAAGGCCCTGT
1261 1271 1281 1291 1301 1311
* * * * * * TCGAGCTCGGGGCAGGGTGGTAGAACAGCTGCAACAGGGACAGGTCTTGCCAGATTAGTG
1321 1331 1341
* * *
CCTTCCATCAGTTGGCGGAATTCG.
12. The DNA fragment of claim 11, wherein said fragment contains a coding sequence homologous to nucleotides 2 through 101 of said first sequence, nucleotides 594 through 643 of said second sequence, or a sequence complementary to said coding sequences.
13. A kit comprising, in a container or separate containers, a pair of single-strand primers derived from non- homologous regions of opposite strands of a DNA duplex fragment derived from an enterically transmitted viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ-KFl(ETl.l) carried in E. coli strain BB4 and having ATCC deposit no. 67717.
14. The kit of claim 13, which are derived from opposite strands of the EcoRI duplex insert in said plasmid.
15. A method for detecting the presence of an enterically transmitted nonA/nonB hepatitis viral agent in a biological sample, comprising ' preparing a mixture of duplex DNA fragments derived from the sample, denaturing the duplex fragments, adding to the denatured DNA fragments, a pair of single-strand primers derived from non- homologous regions of opposite strands of a DNA duplex fragment derived from an enterically transmitted viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ-KFl(ETl.l) carried in E. coli strain BB4, and having ATCC deposit no. 67717, hybridizing said primers to homologous- sequence region of opposite strands of such duplex DNA fragments derived from enterically transmitted nonA/nonB hepatitis agent, reacting the primed fragment strands with DNA polymerase in the presence of DNA nucleotides, to form new DNA duplexes containing the primer sequences, and repeating said denaturing, adding, hybridizing and reacting steps, until a desired degree of amplification of sequences is achieved.
16. The method of claim 15, wherein the primers are derived from opposite strands the EcoRI duplex insert in said plasmid.
17. The method of claim 15, for detecting the presence of viral agent in a sample of cultured cells infected with the agent.
18. A vaccine for immunizing an individual against enterically transmitted nonA/nonB hepatitis viral agent comprising, in a pharmacologically acceptable adjuvant. a recombinant protein derived from an enterically transmitted nonA/nonB viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ-KFl(ETl.l) carried in E. coli strain BB4, and having ATCC deposit no. 67717.
19. The vaccine of claim 18, wherein the protein is derived from the EcoRI insert in said plasmid.
20. In a method of isolating an enterically transmitted non¬ A/nonB viral agent or a nucleic acid fragment produced by the agent, an improvement which comprises: utilizing, as a source of said agent, bile obtained from a human or cynomolgus monkey having an active infection of enterically transmitted non-A/non-B hepatitis.
21. The method of claim 20, wherein the bile is obtained from an infected cynomologus monkey.
22. Human polyclonal anti-serum obtained from a human immunized with a protein derived form an enterically transmitted non-A/non-B viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZ-KFl(ETl.l) carried in E. coli strain BB4 and having ATCC deposit no. 67717.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20899788A | 1988-06-17 | 1988-06-17 | |
US208,997 | 1988-06-17 | ||
US33667289A | 1989-04-11 | 1989-04-11 | |
US336,672 | 1989-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989012641A1 true WO1989012641A1 (en) | 1989-12-28 |
Family
ID=26903718
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1989/002435 WO1989012641A1 (en) | 1988-06-17 | 1989-06-05 | Enterically transmitted non-a/non-b hepatitis viral agent |
PCT/US1989/002648 WO1989012462A1 (en) | 1988-06-17 | 1989-06-16 | Enterically transmitted non-a/non-b hepatitis viral agent |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1989/002648 WO1989012462A1 (en) | 1988-06-17 | 1989-06-16 | Enterically transmitted non-a/non-b hepatitis viral agent |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0419576A4 (en) |
JP (5) | JPH03506026A (en) |
KR (1) | KR0180530B1 (en) |
AU (2) | AU3748489A (en) |
CA (1) | CA1341464C (en) |
SG (1) | SG49225A1 (en) |
WO (2) | WO1989012641A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0419576A1 (en) * | 1988-06-17 | 1991-04-03 | Genelabs Technologies, Inc. | Enterically transmitted non-a/non-b hepatitis viral agent |
WO1991015603A1 (en) * | 1990-04-05 | 1991-10-17 | Genelabs Incorporated | Enterically transmitted non-a/non-b hepatitis viral agent and characteristic epitopes thereof |
US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
US5686239A (en) * | 1988-06-17 | 1997-11-11 | Genelabs Technologies, Inc. | Hepatitis E virus peptides and methods |
US5741490A (en) * | 1988-06-17 | 1998-04-21 | Genelabs Technologies, Inc. | Hepatitis E virus vaccine and method |
US5770689A (en) * | 1988-06-17 | 1998-06-23 | Genelabs Technologies, Inc. | Hepatitis E virus ORF Z peptides |
US5789559A (en) * | 1988-06-17 | 1998-08-04 | Genelabs Technologies, Inc. | DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent |
US5824649A (en) * | 1988-06-17 | 1998-10-20 | Genelabs Technologies, Inc. | DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent and characteristic epitopes thereof |
US6210675B1 (en) | 1989-12-18 | 2001-04-03 | Glaxo Wellcome Inc. | PT-NANB hepatitis polypeptides |
US7166287B1 (en) | 1989-12-18 | 2007-01-23 | Glaxo Wellcome Inc. | Viral agent |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT54896A (en) * | 1989-03-17 | 1991-04-29 | Chiron Corp | Process for producing aquous diagnosticum and vaccine of nanbv |
EP0447984A1 (en) * | 1990-03-20 | 1991-09-25 | Abbott Laboratories | Hyperimmune globulin against hepatitis C virus and method for making same |
AU8544591A (en) * | 1990-09-07 | 1992-03-30 | Board Of Regents Of The University Of Oklahoma, The | Antigens associated with polymyositis and with dermatomyositis |
US6620414B2 (en) | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
MY111880A (en) * | 1992-03-27 | 2001-02-28 | Smithkline Beecham Biologicals S A | Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985001517A1 (en) * | 1983-09-30 | 1985-04-11 | Massachusetts Institute Of Technology | PRODUCTION OF cDNA REPRESENTING HEPATITIS A VIRAL SEQUENCES |
US4591552A (en) * | 1982-09-29 | 1986-05-27 | New York Blood Center, Inc. | Detection of hepatitis B surface antigen (or antibody to same) with labeled synthetic peptide |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
FR2606515B1 (en) * | 1986-11-07 | 1992-02-21 | Pasteur Institut | PROCESS FOR ISOLATING A NEW VIRAL AGENT AND THE ANTIGEN ASSOCIATED WITH IT, VIRAL AGENT AND ANTIGEN OBTAINED THEREBY AND METHOD FOR DETECTING THE SAME ANTIGEN USING AN APPROPRIATE IMMUNOLOGICAL REAGENT |
FR2609807B2 (en) * | 1987-02-11 | 1992-05-29 | Pasteur Institut | IMMUNOLOGICAL REAGENTS FOR THE DETECTION OF NANB VIRAL HEPATITIS, THEIR PREPARATION METHODS AND THEIR APPLICATIONS IN METHODS OF DETECTION OF NANB VIRAL HEPATITIS AND AS THERAPEUTIC AGENTS |
AU3748489A (en) * | 1988-06-17 | 1990-01-12 | Genelabs Incorporated | Enterically transmitted non-a/non-b hepatitis viral agent |
-
1989
- 1989-06-05 AU AU37484/89A patent/AU3748489A/en not_active Abandoned
- 1989-06-05 WO PCT/US1989/002435 patent/WO1989012641A1/en unknown
- 1989-06-15 CA CA000602944A patent/CA1341464C/en not_active Expired - Lifetime
- 1989-06-16 WO PCT/US1989/002648 patent/WO1989012462A1/en not_active Application Discontinuation
- 1989-06-16 AU AU38574/89A patent/AU639209B2/en not_active Expired
- 1989-06-16 SG SG1996007921A patent/SG49225A1/en unknown
- 1989-06-16 JP JP1507371A patent/JPH03506026A/en not_active Withdrawn
- 1989-06-16 KR KR1019900700347A patent/KR0180530B1/en not_active IP Right Cessation
- 1989-06-16 EP EP19890907985 patent/EP0419576A4/en not_active Ceased
-
1999
- 1999-12-22 JP JP11365699A patent/JP2000184895A/en active Pending
-
2001
- 2001-07-19 JP JP2001220744A patent/JP2002097198A/en not_active Withdrawn
-
2004
- 2004-10-20 JP JP2004306268A patent/JP4072604B2/en not_active Expired - Lifetime
-
2006
- 2006-08-09 JP JP2006217544A patent/JP2007031440A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4591552A (en) * | 1982-09-29 | 1986-05-27 | New York Blood Center, Inc. | Detection of hepatitis B surface antigen (or antibody to same) with labeled synthetic peptide |
WO1985001517A1 (en) * | 1983-09-30 | 1985-04-11 | Massachusetts Institute Of Technology | PRODUCTION OF cDNA REPRESENTING HEPATITIS A VIRAL SEQUENCES |
Non-Patent Citations (4)
Title |
---|
JOURNAL OF GENERAL VIROLOGY, Vol. 69, No. 3, issued March 1988, D. BRADLEY et al.: "Aetiological agent of enterically transmitted non-A, non-B hepatitis", pages 731-738, See Summary. * |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, Vol. 84, No. 17, issued September 1987, D.W. BRADLEY et al.: "Enterically transmitted non-A, non-B hepatitis. Serial passage of disease in cynomolgus macaques and tamarins and recovery of disease-associated 27-to 34-NM viruslike particles", pages 6277-6281. See abstract. * |
THE JOURNAL OF INFECTIOUS DISEASE, Vol. 159, No. 6, issued June 1989, K. KRAWCZYNSKI et al.: "Enterically transmitted non-A, non-B hepatitis: Identification of virus-associated antigen in experimentally infected cynomolgus macques", pages 1042-1049. See page 1042 first full paragraph; page 1048 second full paragraph. * |
THE LANCET, Vol. i, No. 8585, issued 12 March 1988, V.A. ARANKALLE et al.: "Aetiological associated of a virus like particle with enterically transmitted non-A, non-B hepatitis", pages 550-554. See Summary. * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
US5770689A (en) * | 1988-06-17 | 1998-06-23 | Genelabs Technologies, Inc. | Hepatitis E virus ORF Z peptides |
EP0419576A4 (en) * | 1988-06-17 | 1991-11-27 | Genelabs, Incorporated | Enterically transmitted non-a/non-b hepatitis viral agent |
US5686239A (en) * | 1988-06-17 | 1997-11-11 | Genelabs Technologies, Inc. | Hepatitis E virus peptides and methods |
US5741490A (en) * | 1988-06-17 | 1998-04-21 | Genelabs Technologies, Inc. | Hepatitis E virus vaccine and method |
EP0419576A1 (en) * | 1988-06-17 | 1991-04-03 | Genelabs Technologies, Inc. | Enterically transmitted non-a/non-b hepatitis viral agent |
US5789559A (en) * | 1988-06-17 | 1998-08-04 | Genelabs Technologies, Inc. | DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent |
US5824649A (en) * | 1988-06-17 | 1998-10-20 | Genelabs Technologies, Inc. | DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent and characteristic epitopes thereof |
US6120988A (en) * | 1988-06-17 | 2000-09-19 | Genelabs Technologies, Inc. | Method of detecting hev infection |
US7094406B2 (en) | 1988-06-17 | 2006-08-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services And Genelabs Technologies, Inc. | Enterically transmitted non-A/non-B hepatitis viral agent and characteristic epitopes thereof |
US6210675B1 (en) | 1989-12-18 | 2001-04-03 | Glaxo Wellcome Inc. | PT-NANB hepatitis polypeptides |
US7166287B1 (en) | 1989-12-18 | 2007-01-23 | Glaxo Wellcome Inc. | Viral agent |
WO1991015603A1 (en) * | 1990-04-05 | 1991-10-17 | Genelabs Incorporated | Enterically transmitted non-a/non-b hepatitis viral agent and characteristic epitopes thereof |
Also Published As
Publication number | Publication date |
---|---|
SG49225A1 (en) | 1998-05-18 |
JP4072604B2 (en) | 2008-04-09 |
KR900701317A (en) | 1990-12-01 |
WO1989012462A1 (en) | 1989-12-28 |
AU639209B2 (en) | 1993-07-22 |
JP2000184895A (en) | 2000-07-04 |
AU3748489A (en) | 1990-01-12 |
JP2007031440A (en) | 2007-02-08 |
JPH03506026A (en) | 1991-12-26 |
AU3857489A (en) | 1990-01-12 |
KR0180530B1 (en) | 1999-03-20 |
EP0419576A1 (en) | 1991-04-03 |
EP0419576A4 (en) | 1991-11-27 |
JP2005053924A (en) | 2005-03-03 |
JP2002097198A (en) | 2002-04-02 |
CA1341464C (en) | 2004-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007031440A (en) | Enterically transmitted non-a non-b hepatitis viral factor | |
EP0476130B1 (en) | Enterically transmitted non-a/non-b hepatitis viral agent and characteristic epitopes thereof | |
CA2032381C (en) | Viral agent | |
KR0181517B1 (en) | Non-a, non-b hepatitis-specific antigen and its use in hepatitis diagnosis | |
US5770689A (en) | Hepatitis E virus ORF Z peptides | |
AU4046489A (en) | Post-transfusion, non-a, non-b hepatitis virus and antigens | |
JP2001269185A (en) | Hepatitis c virus epitope | |
IE83236B1 (en) | Hepatitis C virus epitopes | |
US5218099A (en) | Post-transfusion, non-A, non-B hepatitis virus polynucleotides | |
US5885768A (en) | Hepatitis E virus peptide antigen and antibodies | |
US5741490A (en) | Hepatitis E virus vaccine and method | |
US5789559A (en) | DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent | |
US5824649A (en) | DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent and characteristic epitopes thereof | |
JPH06507552A (en) | DNA sequences and encoded polypeptides useful in the diagnosis of hepatitis diseases | |
CN1048523C (en) | Enterically transmitted non-A/non-B hepatitis viral agent | |
JPH0584085A (en) | Dna fragment encoding non-a non-b type hepatitis specific antigen, its manifestation and method for detecting non-a non-b type hepatitis virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |